0	AURICULAR
0	KELOIDS
0	RECURRED
0	TREATMENT
0	PREVIOUS
0	HAVE
1	INCREASED
1	RECURRENCE
1	HAVE
1	LIKELIHOOD
2	BEST
2	HOW
2	AURICULAR
2	KELOIDS
2	TREAT
2	CONSENSUS
3	HERE
3	PERFORM
3	META-ANALYSIS
3	META
3	ANALYSIS
3	AURICULAR
3	KELOIDS
3	EVIDENCE
3	INVESTIGATING
3	EVIDENCE FOR
3	REVIEW
3	TREATING
3	SYSTEMATIC REVIEW
4	KEYWORDS
4	EBM
4	USING
4	SPECIFIC
4	MEDLINE
4	SEARCHED
4	EMBASE
4	REVIEWS
5	CRITERIA
5	USED
5	ELIGIBILITY
5	INCLUSION AND EXCLUSION
5	INCLUSION
5	EXCLUSION CRITERIA
5	ASSESS
5	EXCLUSION
5	ARTICLE
6	NUMBER
6	KELOIDS
6	EXTRACTED
6	MINIMUM
6	FOLLOW-UP
6	DATA
6	NUMBER OF
6	FOLLOW
6	TREATMENT
6	RECURRENCE
6	MODALITY
6	TIME
7	META
7	OXFORD
7	MEDICINE GUIDELINES
7	LEVEL OF EVIDENCE
7	OF EVIDENCE
7	TREATMENT
7	BASED
7	EVIDENCE-BASED MEDICINE
7	CENTRE
7	META-ANALYSIS
7	MEDICINE
7	EVIDENCE
7	PERFORMED
7	LEVEL
7	CONFIDENCE INTERVALS
7	MODALITY
7	ESTIMATE
7	INTERVALS
7	ANALYSIS
7	CONFIDENCE
7	LOE
7	ARTICLES
7	RECURRENCE RATES
7	INCLUDED
7	RATES
7	ASSIGNED
7	STRATIFIED
7	GUIDELINES
7	RECURRENCE
8	ARTICLES
8	IDENTIFIED
8	UNIQUE
8	INCLUDED
8	TOTAL
8	887
9	LOE
9	III
10	COMPRESSION
10	STEROID
10	RADIATION
10	FOUND
10	RECURRENCE RATES
10	THERAPY
10	EXTERNAL BEAM RADIATION
10	ADJUVANT
10	BEAM
10	RECURRENCE
10	RATES
10	COMPRESSION THERAPY
10	EXTERNAL
10	BEAM RADIATION
10	INJECTIONS
10	BRACHYTHERAPY
10	EXCISION
11	FOUND
11	SIGNIFICANT
11	DIFFERENCE
11	STATISTICAL
12	AURICULAR
12	KELOIDS
12	DATA
12	TREATMENT
12	QUALITY
12	STUDIES
12	HIGH
12	HETEROGENEOUS
13	ANALYSIS
13	LOWEST
13	RECURRENCE RATE
13	OUR
13	ADJUVANT
13	RECURRENCE
13	RATE
13	BRACHYTHERAPY
13	EXCISION
14	CONFIDENCE
14	HERE
14	COMPRESSION
14	EITHER
14	SURGEONS
14	NARROW
14	HELP
14	THERAPY
14	MODALITIES
14	RECOMMEND
14	TREATMENT
14	THESE
14	PATIENTS
14	COMPRESSION THERAPY
14	CONFIDENCE INTERVALS
14	BRACHYTHERAPY
14	REPORTED
14	INTERVALS
16	OBJECTIVES
17	NON
17	TO TEST
17	TEST
17	RESTAURANT
17	LABELLING
17	KNOWLEDGE
17	ALCOHOLIC
17	CALORIE
17	NON-
17	INFLUENCE
17	ORDERS
17	BEVERAGE
17	PERCEIVED
17	ALCOHOLIC BEVERAGES
17	HYPOTHETICAL
17	BEVERAGES
17	INFORMATION
17	ACTUAL
17	EFFICACY
18	UPPER
18	PARTICIPANTS
18	STUDENTS
18	LEGAL DRINKING AGE
18	DRINKING
18	LEVEL
18	LEGAL
18	AGE
18	ONTARIO
18	CANADA
18	INCLUDED
18	ONTARIO, CANADA
18	UNIVERSITY
19	METHODS
20	EXPERIMENT
20	RANDOMIZED
20	PARTICIPANTS
20	CALORIE
20	CONTROL
20	ADJACENT TO
20	BEVERAGE
20	USING
20	INFORMATION
20	ADJACENT
20	ONE OF
20	GROUPS
20	VIEW
21	COMPLETED
21	ORDERING
21	PARTICIPANTS
21	CALORIE
21	PERCEIVED
21	TASK
21	HYPOTHETICAL
21	RELATED
21	INFLUENCE
21	BEVERAGES
21	ORDERED
21	ASSESSED
21	MEASURES
21	INFORMATION
21	ACTUAL
21	KNOWLEDGE
22	REGRESSION MODELS
22	LOGISTIC REGRESSION MODELS
22	USED
22	REGRESSION
22	MODELS
22	LOGISTIC
22	OUTCOMES
22	LINEAR
22	TO EXAMINE
22	MULTINOMIAL LOGISTIC REGRESSION
22	LOGISTIC REGRESSION
23	ODDS
23	CALORIE
23	CONDITION
23	16.8
23	INFORMATION
23	113
23	VERSUS
23	HIGHER
24	RESULTS
25	0.2
25	ODDS
25	PARTICIPANTS
25	CALORIE
25	ORDERED
25	COMPARED
25	BEVERAGES
25	0.09
25	CONDITION
25	INFORMATION
25	0.02
25	DON
25	CALORIES
25	ESTIMATING
25	DON'T KNOW
25	LOWER
26	NUMBER
26	CALORIE
26	PERCEIVED
26	CONDITIONS
26	ORDERED
26	INFLUENCE
26	SIGNIFICANT
26	BEVERAGES
26	NUMBER OF
26	MENU
26	INFORMATION
26	OBSERVED
26	LABELLING
26	CALORIES
27	NON
27	ALCOHOLIC
27	CALORIE
27	NON-
27	ALCOHOLIC BEVERAGES
27	ORDERED
27	BEVERAGES
27	EXPOSURE TO
27	ESTIMATING
27	INFORMATION
27	EXPOSURE
27	INCREASED
27	CALORIES
27	CONSUMERS
28	CONCLUSION
29	BACKGROUND
30	CONCERN
30	RESISTANT
30	GLOBAL
30	METICILLIN
30	STAPHYLOCOCCAL INFECTIONS
30	INFECTIONS
30	STAPHYLOCOCCAL
31	EXAM
31	DERMATOLOGY
31	VETERINARY
31	PYODERMA
31	GIVEN
31	ROOM
31	SURFACES
31	MAY BE A
31	MAY BE
31	RESERVOIR
31	STAPHYLOCOCCAL
32	HYPOTHESIS
32	OBJECTIVES
33	EXAM
33	AMMONIUM COMPOUND
33	QUATERNARY AMMONIUM
33	DIFFERENT
33	COMPOUND
33	USE OF
33	INSTRUCTION
33	QUATERNARY AMMONIUM COMPOUND
33	AMMONIUM
33	USING
33	CLEANING
33	DECONTAMINATION
33	PROTOCOLS
33	SURFACE
33	USE
33	ASSESSED
33	ROOM
33	EFFICACY
33	A QUATERNARY AMMONIUM
34	ROOMS
34	USE OF
34	COAGULASE
34	USE
34	PYODERMA
34	COPS
34	ASSESSED
34	DOGS
34	COUNTS
34	POSITIVE
34	COLONY
34	SECOND
34	DISINFECTION
34	CLEANING
34	STAPHYLOCOCCAL
35	METHODS
35	MATERIALS
36	PROTOCOLS
36	FLUORESCENT
36	SURFACE
36	DYE
36	TAGGED
36	ROOM
36	BASED
36	SURFACES
36	GLO
36	EFFICACY
36	GERM
36	CLEANING
36	ASSESS
36	FLUORESCENT DYE
37	EXPRESS
37	COPS
37	COLONIES
37	SYSTEM
37	STAPH
38	SAMPLED
38	PYODERMA
38	USE
38	IMMEDIATELY
38	DETAILED
38	ROOM
38	PROTOCOL
38	SURFACES
38	DOG
38	DISINFECTION
38	CLEANING
38	STAPHYLOCOCCAL
38	USE BY
39	RESULTS
40	PROTOCOLS
40	CLEANED
40	COMPLETELY
40	100
40	DETAILED
40	SURFACES
40	TOTAL
40	GENERAL
41	NUMBER
41	CLEANED
41	MEAN
41	NUMBER OF
41	DETAILED
41	PROTOCOL
41	SURFACES
41	003
41	HIGHER
42	CHAIRS
42	REDUCED
42	COPS
42	COUNTS
42	DETAILED
42	COLONY
42	PROTOCOL
42	SURFACES
43	EXAM
43	COPS
43	TABLE
43	ISOLATED
43	MAT
44	CONCLUSIONS
44	CLINICAL RELEVANCE
44	RELEVANCE
44	CLINICAL
45	PROTOCOLS
45	EXAM
45	VETERINARY
45	DETAILED
45	ROOM
45	RECOMMENDED
45	SURFACES
45	DISINFECTION
45	CONTAMINATION
45	CLEANING
46	CHAIRS
46	DISINFECTION
46	APPROPRIATE
46	STUDY
47	APPARENT
47	WELLNESS
47	STUDENTS
47	EVIDENCE
47	MEDICAL STUDENT
47	WORSENING
47	DETERIORATES
47	CANADA
47	MEDICAL STUDENTS
47	STUDENT
47	PROBLEM
47	TRAINING
47	MEDICAL
47	IS A
48	FRAMEWORKS
48	COMPETENCY
48	SCHOOLS
48	INTEGRATING
48	WELLNESS
48	COMBINATION
48	INDIVIDUAL
48	APPROACHES
48	MEDICAL SCHOOLS
48	BODIES
48	LEVEL
48	SYSTEM
48	ACCREDITATION
48	STANDARDS
48	MEDICAL
49	ESSENTIAL
49	IMPACT
49	BURNOUT
49	OUTCOMES
49	STUDENT
49	REDUCING
49	HOW
49	HIDDEN
49	CONSIDER
49	LEVEL
49	CURRICULUM
49	MEDICAL
49	OPTIMAL
49	STRATEGIES
49	POLICIES
49	PREVALENCE
49	WELLNESS
49	SYSTEM
49	CULTURE
50	PROGRAMMING
50	WELLNESS
50	WIDESPREAD
50	USED
50	INDIVIDUAL
50	LEVEL
50	INITIATIVES
51	ENVIRONMENT
51	ADDRESSING
51	PLACING
51	THESE
51	STUDENT
51	ONUS
51	LEARNING ENVIRONMENT
51	LEARNING
52	PROGRAMMING
52	SCHOOLS
52	ACROSS
52	LEVELS
52	SIGNIFICANT
52	CONSISTENCY
52	PROGRESS
52	LITTLE
52	TRAINING
53	EDUCATION
53	CANADIAN
53	WELLNESS
53	UNDERGRADUATE
53	COMPETENCIES
53	RESIDENCY
53	MEDICAL EDUCATION
53	UNDERGRADUATE MEDICAL EDUCATION
53	FRAMEWORK
53	CURRICULUM
53	MEDICAL
54	SMOOTH
54	INDIVIDUAL
54	HELP
54	MEDICAL SCHOOL
54	TRANSITION
54	LEVEL
54	SYSTEM
54	INITIATIVES
54	RESIDENCY
54	CREATING
54	ALIGN
54	FRAMEWORK
54	MEDICAL
54	SCHOOL
55	ORGANIZE
55	ADAPTABILITY
55	INFORMED
55	WELLNESS
55	BASIC
55	CONSIDER
55	LEARNER
55	ALLOW
55	GOALS
55	LOCAL
55	FRAMEWORK
55	RELEVANT
55	NEEDS
56	WORK
56	HEALTHY
56	POPULATION
56	WELLNESS
56	ENVIRONMENTS
56	CANADIAN
56	CONTRIBUTE 
56	PATIENT
56	SUSTAINING
56	CONTRIBUTE
56	CARE
56	PATIENT CARE
56	QUALITY
56	SUPPORTED
56	WORK ENVIRONMENTS
56	TRAINING
56	PHYSICIANS
57	2017
57	IDENTIFICATION
57	2019
57	MOSQUITOES
57	LOCATIONS
57	DIFFERENT
57	QATAR
58	PUBLIC
58	PUBLIC HEALTH
58	HEALTH
58	MOSQUITO
58	CONSEQUENCES
58	CONSIDERABLE
58	BORNE
58	INFECTIONS
58	HAVE
59	CASE
59	PRESENCE OF
59	VBD
59	VECTOR
59	ENVIRONMENTAL
59	ASSOCIATED WITH
59	LOCAL
59	BORNE
59	PRESENCE
59	DISEASE
59	THE MERE
59	HOST
59	SUITABLE
59	SINGLE
59	VECTOR-BORNE DISEASE
59	VECTOR-BORNE
59	RISK
59	ASSOCIATED
59	ENVIRONMENTAL FACTORS
59	COMPATIBLE
59	MERE
59	COMMUNITY
59	INTRODUCES
60	ESTABLISHED
60	VECTOR CONTROL
60	SPREADING
60	CONTROL
60	LIKELIHOOD
60	VECTOR
60	PRESENTLY
60	UNDETERMINED
60	PROGRAMME
60	QATAR
60	SURVEILLANCE
61	PRESSING
61	RESULT
61	GAP
61	SUCCESSFUL
61	MANAGEMENT
61	NEED
61	ADDRESS
61	ENABLE
61	IS A
62	PUBLIC HEALTH
62	2019
62	DEFINING
62	2017
62	FIELD SURVEYS
62	MOSQUITOES
62	PUBLIC
62	CONSECUTIVE
62	STUDY
62	DISTRIBUTION
62	SURVEYS
62	RESULTS
62	HEALTH
62	IMPORTANCE
62	TYPES
62	AIM
62	FIELD
62	QATAR
62	PRESENTS
63	CULEX
63	SPECIES
63	WIDESPREAD
63	HOUSE
63	ABUNDANT
63	WEST
63	VIRUS
63	TRANSMISSION
63	SOUTHERN HOUSE MOSQUITO
63	CULEX QUINQUEFASCIATUS
63	SOUTHERN
63	ADULT
63	FOLLOWED
63	RISK
63	RISK OF
63	RESULTS
63	MOSQUITO
63	FOLLOWED BY
63	WEST NILE VIRUS
64	ANOPHELES STEPHENSI
64	WIDESPREAD
64	TRANSMISSION
64	RISK
64	MALARIA
64	METHODS
64	VECTOR
64	RISK OF
64	AREAS
64	ANOPHELES
64	LOCAL
64	MALARIA TRANSMISSION
64	SAMPLING
64	MALARIA VECTOR
64	INCLUDING
65	VIRUS
65	WIDESPREAD
65	RIFT VALLEY FEVER
65	RISK
65	AEDES CASPIUS
65	TRANSMISSION
65	RISK OF
65	FEVER
65	MOSQUITO
65	RIFT VALLEY
65	VALLEY FEVER
65	WETLAND
65	RIFT
65	AEDES
65	VALLEY
65	RIFT VALLEY FEVER VIRUS
66	MINIMAL RISK
66	CHIKUNGUNYA
66	WIDESPREAD
66	MINIMAL
66	RISK
66	TRANSMISSION
66	VECTOR
66	DENGUE
66	NEITHER
66	ZIKA
66	LOCAL TRANSMISSION
66	ABUNDANT
66	LOCAL
66	NOT DETECTED
66	VIRUSES
66	DETECTED
66	CONSIDERED
66	DENGUE VECTOR
67	STUDY
67	CULISETA 
67	DETECTED
67	TIME
67	CULISETA LONGIAREOLATA
67	QATAR
67	CULISETA
68	SPECIES
68	DISEASES
68	ADDRESS
68	DIFFERENT
68	KNOWLEDGE
68	PRESENT
68	REGULAR
68	BORNE
68	TERMS
68	DISTRIBUTION
68	GAPS
68	NEEDED
68	ECOLOGY
68	HABITS
68	QATAR
68	BITING
68	CURRENTLY
68	RISK
68	RISK OF
68	MOSQUITO-BORNE DISEASES
68	MOSQUITO
68	STUDIES
68	FIELD
68	ASSESS
69	EXPERIENCE
69	DISPARITIES
69	HEART
69	WOMEN
69	MANAGEMENT
69	CONDITION
69	TREATMENT
69	HEART DISEASE
69	DIAGNOSIS
69	DISEASE
70	RESPECT
70	EXPERIENCE
70	PATIENT
70	SEX DIFFERENCES
70	UNKNOWN
70	SEX
70	THESE
70	HOSPITAL PATIENT
70	HOSPITAL
70	EXIST
71	COMPREHENSIVE
71	EXPERIENCE
71	DUE TO
71	ACROSS
71	HEART
71	ACCORDING
71	ISCHEMIC HEART DISEASE
71	ALBERTA, CANADA
71	ALBERTA
71	HOSPITALIZED
71	CANADA
71	EXAMINED
71	HEART DISEASE
71	IHD
71	ISCHEMIC
71	SEX
71	PATIENTS
71	DISEASE
72	COMPLETED
72	CPES
72	MODIFIED
72	VERSION
72	SURVEY
72	CANADIAN
72	EXPERIENCES
72	INPATIENT
72	INPATIENT CARE
72	6 WEEKS
72	WEEKS
72	PATIENT
72	CARE
72	MODIFIED VERSION
72	DISCHARGE
72	PATIENTS
73	GLOBAL
73	PROCESSES
73	SCALES
73	SPECIFIC
73	CARE
73	EXAMINED
73	GLOBAL RATING
73	RATING SCALES
73	RATING
73	INCLUDING
74	ANSWER
74	BOX
74	QUESTION
74	SURVEY
74	POSITIVE
74	RESPONSES
74	CHOICE
74	REPORTED
74	RAW
75	CONFIDENCE
75	DEMOGRAPHIC
75	BOX
75	QUESTION
75	ODDS
75	WOMEN
75	CLINICAL
75	CALCULATED
75	CONTROLLING
75	REPORTING
75	CLINICAL FACTORS
75	CONFIDENCE INTERVALS
75	RESPONSE
75	INTERVALS
76	COMPLETED
76	MEN
76	WOMEN
76	2014
76	APRIL
76	MARCH
76	TOTAL
76	SURVEYS
76	2020
77	BOX
77	ACCOUNT
77	SURVEY
77	WOMEN
77	MARGIN
77	ERROR
77	TAKING
77	LOWER
78	OBTAINED
78	ADJUSTED
78	BOX
78	ODDS
78	RESULTS
78	SIMILAR
78	REPORTING
78	RESPONSE
79	BOX
79	WOMEN
79	PERCENTAGE
79	RESPONSES
79	DID NOT HAVE
79	HAVE
79	HIGHER
79	DID
80	STUDY
80	CANADIAN
80	EXPERIENCES
80	HEART
80	STRATIFIED
80	ACCORDING
80	ISCHEMIC HEART DISEASE
80	HOSPITALIZED
80	PATIENTS
80	HEART DISEASE
80	SEX
80	HOSPITALIZED PATIENTS
80	ISCHEMIC
80	IS A
80	LIVING
80	DISEASE
81	IMPORTANT
81	OUR
81	SEX DIFFERENCES
81	RESULTS
81	SEX
82	EXPERIENCES
82	PATIENT-REPORTED
82	ASSOCIATED
82	SEX DIFFERENCES
82	PATIENT
82	MECHANISMS
82	FUTURE
82	REPORTED
82	IN PATIENT
82	ASSOCIATED WITH
82	THESE
82	SEX
82	OBSERVED
82	RESEARCH
82	UNDERSTAND
84	OBJECTIVE
85	USE
85	ACROSS
85	ONE HEALTH
85	ANTIMICROBIAL RESISTANCE
85	AMU
85	IMPORTANT
85	EVIDENCE
85	STEWARDSHIP
85	CONTROL
85	AMR
85	ANTIMICROBIAL
85	INTEGRATED
85	HEALTH
85	BASED
85	RESISTANCE
85	EFFECTIVE
85	POLICY
85	SURVEILLANCE
86	COMPREHENSIVE
86	SURVEILLANCE
86	OBJECTIVE
86	AMU
86	OUR
86	AMR
86	INTEGRATED
86	PROGRESS
86	CANADA
86	EVALUATE
87	METHODS
87	MATERIALS
88	COMPONENTS
88	INFECTIOUS DISEASES
88	CORE
88	VETERINARY
88	MATTER
88	CANADIAN
88	DISEASES
88	COUNCIL
88	BASED
88	DEVELOPMENT STAGE
88	CENTRE
88	2016
88	DEVELOPMENT
88	SUBJECT
88	INTERVIEWS
88	2014
88	ENVIRONMENTAL
88	IDENTIFIED
88	REQUIREMENTS
88	MATRIX
88	RANKED
88	SCAN
88	INFECTIOUS
88	WAY
88	USING
88	NATIONAL
88	COMMON
88	CLASSIFICATION
88	ELEMENTS
88	REPORTS
88	ASSESSED
88	ACCORDING
88	SPECIFIC
88	STAGE
88	SURVEILLANCE
89	RESULTS
90	COMPONENTS
90	COMPREHENSIVE
90	FULLY
90	SURVEILLANCE
90	SURVEILLANCE SYSTEM
90	LOWEST
90	DEVELOPMENT
90	AMU
90	STAGES
90	AMR
90	SYSTEM
90	REQUIREMENTS
90	ADOPTION
90	MAPPED
90	EXPLORATION
90	PROGRAM
90	INTEGRATED
91	COMPONENTS
91	SURVEILLANCE SYSTEM
91	CANADIAN
91	INFECTION SURVEILLANCE
91	AMR
91	SYSTEM
91	INTEGRATED
91	EXPANSION
91	INFECTION
91	NOSOCOMIAL INFECTION
91	REPORTING
91	SURVEILLANCE PROGRAM
91	EXISTING
91	PROGRAM
91	ESTABLISHMENT
91	SURVEILLANCE
92	COMPREHENSIVE
92	CANADIAN
92	BEING
92	PREVENT
92	ONE HEALTH
92	REGARDLESS
92	AMU
92	AMR
92	INTEGRATED
92	HEALTH
92	GAPS
92	OBVIOUS
92	PROGRAM
92	SURVEILLANCE
93	CONCLUSION
94	SUCCESS
94	PROVINCIAL
94	BASED
94	DEVELOPMENT
94	CHANGES
94	PERSONS
94	COMPLETE
94	DEDICATED
94	AMR
94	FUNDING
94	AMU
94	FEDERAL
94	REPORTING
94	POLICIES
94	RESOURCES
94	NEEDED
94	ACTION
94	INTEGRATED
94	AREAS
94	SURVEILLANCE PROGRAM
94	CURRENT
94	TERRITORIAL
94	ENABLING
94	STRUCTURES
94	PROGRAM
94	POLICY
94	SURVEILLANCE
94	III
96	PURPOSE
97	OVERDOSE
97	CHILDREN
97	RISK
97	PRESCRIPTIONS
97	ADDICTION
97	ADOLESCENTS
97	RISK OF
97	MISUSE
97	OPIOIDS
97	OPIOID
97	INCREASE
98	INPATIENT
98	DETERMINE
98	TO DESCRIBE
98	OPIOID
98	DISCHARGE
98	DESCRIBE
98	CHARACTERISTICS
98	PATIENT
98	ASSOCIATED WITH
98	FOLLOWING
98	OPIOID ANALGESICS
98	VISITS
98	PRESCRIPTION
98	PATTERNS
98	STUDY
98	PROLONGED
98	ANALGESICS
98	ASSOCIATED
98	PRESCRIBING
99	METHODS
100	DISCHARGED FROM HOSPITAL
100	ANALGESIC
100	HOSPITAL
100	OPIOID
100	2017
100	PATIENTS
100	HISTORICAL
100	2016
100	IDENTIFIED
100	HISTORICAL COHORT
100	JANUARY
100	PRESCRIPTION
100	COHORT STUDY
100	STUDY
100	DISCHARGED
100	PEDIATRIC HOSPITAL
100	PEDIATRIC
100	COHORT
100	HISTORICAL COHORT STUDY
100	OPIOID ANALGESIC
100	JUNE
100	TERTIARY
101	NUMBER
101	OUTCOME
101	OPIOID
101	PRIMARY
101	NUMBER OF
101	NUMBER OF DAYS
101	DAYS
101	DURATION
101	PRIMARY OUTCOME
101	PRESCRIPTION
102	CHARACTERISTICS
102	PRESCRIPTION
102	ACCOUNT
102	CLUSTERING
102	DUE TO
102	REPEATED
102	ASSESSED
102	ADMISSIONS
102	PATIENT
102	USING
102	GENERALIZED
102	DAYS
102	EQUATION
102	DURATION
102	OPIOID
102	ESTIMATING
102	ASSOCIATION
102	ESTIMATING EQUATION
103	RESULTS
104	STUDY
104	ADMITTED
104	AT DISCHARGE
104	MONTH
104	787
104	15.4
104	PRESCRIPTIONS
104	GIVEN
104	PERIOD
104	TOTAL
104	OPIOID
104	DISCHARGE
104	PATIENTS
104	870
105	RANGE
105	OUTPATIENT
105	3.75
105	MEDIAN
105	OPIOID THERAPY
105	THERAPY
105	DAYS
105	INTERQUARTILE RANGE
105	DURATION
105	OPIOID
105	PRESCRIBED
106	PERCENT
106	PRESCRIPTIONS
106	SEVEN
106	DAYS
106	SEVENTY
106	SEVENTY-SEVEN
106	OPIOID
107	ANALYSIS
107	REVEALED
107	CLINICAL
107	SERVICE
107	ASSOCIATED
107	OPIOID
107	HOSPITAL
107	GENERALIZED
107	DAYS
107	OXYCODONE
107	EQUATION
107	ASSOCIATED WITH
107	HOSPITAL STAY
107	ORTHOPEDICS
107	DISCHARGE
107	ESTIMATING
107	PRESCRIPTION
107	ESTIMATING EQUATION
108	CONCLUSIONS
109	ADULTS
109	CHILDREN
109	CONSISTENT
109	LESS THAN
109	GUIDELINES 
109	GUIDELINES
109	OPIOIDS
109	DAYS
109	CURRENT
109	LESS THAN FIVE
109	CONSISTENT WITH
109	DISCHARGE
109	PRESCRIBED
110	AFFECTS
110	NOVEL
110	PREEXISTING
110	PUBLIC HEALTH
110	GLOBAL
110	CORONAVIRUS
110	CONDITIONS
110	2019
110	CORONAVIRUS DISEASE 2019
110	NOVEL CORONAVIRUS
110	HEALTH
110	CRISIS
110	PREEXISTING CONDITIONS
110	CORONAVIRUS DISEASE
110	IS A
110	PUBLIC
110	DISEASE
111	CARDIOVASCULAR
111	CAUSE OF DEATH
111	RISK
111	CAUSE
111	INACTIVITY
111	OBESITY
111	CVD
111	RISK FACTORS
111	CARDIOVASCULAR DISEASE (CVD)
111	PHYSICAL
111	KEY
111	CARDIOVASCULAR DISEASE
111	PHYSICAL INACTIVITY
111	DEATH
111	SEDENTARY
111	BEHAVIOUR
111	LEADING
111	DISEASE
112	REDUCING
112	LIMIT
112	SPREAD
112	CORONAVIRUS
112	SOCIAL CONTACT
112	CONTACT
112	AT HOME
112	2019
112	HOME
112	IMPLEMENTED
112	SOCIAL
112	SELECT
112	RECOMMENDED
112	LIMITING
112	LARGE
112	GOVERNMENTS
112	HAVE
113	PUBLIC
113	NEGATIVE
113	PUBLIC HEALTH
113	MOVEMENT
113	BEHAVIOURS
113	MAY HAVE
113	HEALTH
113	HOUR
113	CONSEQUENCES
113	UNINTENDED
113	HAVE
114	PURPOSE
114	PROVIDE
114	RECOMMENDATIONS
114	SLEEP
114	ACTIVITY
114	AT-
114	SEDENTARY TIME
114	PRIMARY
114	TO PROVIDE
114	CVD
114	HOME
114	PHYSICAL
114	PRIMARY PURPOSE
114	TIME
114	SEDENTARY
114	REVIEW
114	PHYSICAL ACTIVITY
114	LIVING
115	ADULTS
115	PUBLIC HEALTH
115	SEDENTARY TIME
115	BENEFIT
115	SLEEP PATTERNS
115	CVD
115	TIME
115	SEDENTARY
115	EXERCISE
115	AT HOME
115	PURPOSEFUL
115	PUBLIC
115	ADHERING
115	PATTERNS
115	SLEEP
115	MAINTAIN
115	REDUCE
115	OPTIMAL
115	TO REDUCE
115	RECOMMENDATIONS
115	BEING
115	HOME
115	HEALTH
115	INCREASE
116	III
116	CAPACITY
116	DAYS
116	TIME
116	SITTING
116	USE OF
116	EXERCISE
116	REGULAR
116	SCALES
116	EXERCISE CAPACITY
116	FOLLOWING
116	SELF
116	PURPOSEFUL
116	SCHEDULE
116	PER WEEK
116	MOVING
116	SLEEP
116	2-3 DAYS
116	WEARABLE DEVICES
116	MODERATE
116	MAINTAINING
116	OUR
116	MONITORING
116	DAYS PER
116	EXERCISE INTENSITY
116	WEEK
116	DAILY
116	INCLUDE
116	3 DAYS
116	SELF-MONITORING
116	WEARABLE
116	HIGH
116	RECOMMENDATIONS
116	DAYS PER WEEK
116	INTENSITY
116	USE
116	DEVICES
116	LOW
116	2-3
116	ENGAGING
117	SEDENTARY TIME
117	LIMITING
117	CVD
117	TIME
117	AWARE
117	EXERCISE
117	REGULAR
117	PHYSICAL
117	LIVING
117	ASSOCIATION
117	RESPOND
117	CLEAR
117	SLEEP
117	OPTIMAL
117	PROLONGED
117	REGULAR PHYSICAL ACTIVITY
117	PHYSICAL ACTIVITY
117	ADVICE
117	CHALLENGES
117	ACTIVITY
117	COMMUNICATION
117	PANDEMIC
117	IMPORTANCE
117	CLINICIANS
117	SEDENTARY
117	ENGAGING
118	MAINTENANCE HEMODIALYSIS
118	ANEMIA
118	MEDICATIONS
118	INTRAVENOUS (IV)
118	THESE
118	PATIENTS
118	PROGRAMS
118	ERYTHROPOIETIN
118	SIGNIFICANT
118	INTRAVENOUS
118	MAINTENANCE
118	ASSOCIATED WITH
118	ESAS
118	STANDARD
118	COSTS
118	HEMODIALYSIS
118	RECEIVING
118	IRON
118	TREATMENTS
118	STIMULATING
118	ASSOCIATED
119	TRIAL
119	CARDIOVASCULAR
119	CARDIOVASCULAR OUTCOMES
119	EVIDENCE
119	ESA
119	IMPROVES
119	USAGE
119	DOSE
119	RECENT
119	IV IRON
119	PROTOCOL
119	OUTCOMES
119	HIGH-DOSE
119	HIGH
119	DEMONSTRATED
119	IRON
120	PUBLIC
120	CONTEXT
120	REMAINS
120	CANADIAN
120	HEALTHCARE
120	COST
120	DOSE
120	PROTOCOL
120	PUBLIC HEALTHCARE
120	HIGH-DOSE
120	HIGH
120	IRON
120	UNKNOWN
121	CANADIAN
121	PRIMARY
121	IV IRON
121	PROTOCOL
121	ESTIMATE
121	COSTS
121	STRATEGY
121	HEMODIALYSIS
121	OUR
121	LARGE
121	HIGH
121	LOW-DOSE
121	IRON
121	USES
121	CURRENTLY
121	REACTIVE
121	DOSE
121	LOW
121	AIM
121	HIGH-DOSE
121	PROGRAM
122	USE
122	MAINTAIN
122	COST
122	NEUTRALITY
122	OUR
122	ESA
122	REDUCTION
122	SECONDARY
122	DOSE
122	IV IRON
122	PROTOCOL
122	AIM
122	HIGH-DOSE
122	ESTIMATE
122	HIGH
122	TO MAINTAIN
122	REQUIRED
122	IRON
123	HEMODIALYSIS
123	STUDY
123	TRIAL
123	CHANGES
123	ESA
123	PUBLISHED
123	DATA
123	MEDICATION
123	IV IRON
123	REGIONAL
123	CALCULATED
123	BASED
123	EFFECTS
123	OBSERVED
123	PROGRAM
123	MODELING
123	IRON
124	AUDIT
124	ANEMIA
124	COST
124	QUALITY IMPROVEMENT
124	MANAGEMENT
124	ESTIMATED
124	DATA
124	USING
124	IMPROVEMENT
124	ANEMIA MANAGEMENT
124	MEDICATION
124	CONDITIONS
124	REGIONAL
124	VARIOUS
124	QUALITY
124	POTENTIAL
124	MODELING
125	RENAL
125	ALBERTA
125	BASED
125	HOSPITAL
125	PERIOD
125	CARE
125	OBSERVATION
125	2018
125	HEMODIALYSIS
125	SOUTH
125	SEPTEMBER
125	UNITS
125	ADULT
125	IN-CENTER
125	NOVEMBER
125	OBSERVATION PERIOD
125	CENTER
125	KIDNEY
125	PROGRAM
125	COMMUNITY
126	826
126	DATA
126	INCLUDED
126	TOTAL
126	PATIENTS
127	OBTAINED
127	ELECTRONIC MEDICAL
127	AUDIT
127	ELECTRONIC MEDICAL RECORD
127	MEAN
127	MEDICAL RECORD
127	ESA
127	DATA
127	RECORD
127	IV IRON
127	DOSES
127	ELECTRONIC
127	ROUTINE
127	MONTHLY
127	MEDICAL
127	IRON
128	DETERMINED
128	COSTS
128	MEDICATION
128	PRICES
129	HEMODIALYSIS
129	AGGREGATED
129	DOSAGES
129	ERYTHROPOIETIN
129	LEVEL
129	HEMODIALYSIS UNIT
129	UNIT
129	CURRENT
129	IV IRON
129	IRON
130	TRIAL
130	USED
130	ESA
130	PIVOTAL TRIAL
130	RESULTS
130	EXPECTED
130	REDUCTION
130	IV IRON
130	DOSE
130	PROTOCOL
130	HIGH
130	HIGH-DOSE
130	ESTIMATE
130	INCREASE
130	IRON
131	VARIOUS
131	COST
131	MODEL
131	SPLIT
131	ESA
131	MAINTAINED
131	OUR
131	IV IRON
131	ASSUMED
131	IRON
132	HEMODIALYSIS
132	USED
132	MEAN
132	AGGREGATED
132	PATIENT
132	HEMODIALYSIS UNIT
132	MEDICATION
132	TOTAL
132	COSTS
132	UNIT
132	ESTIMATE
133	MODELS
133	BASED
133	HOSPITAL
133	SENSITIVITY ANALYSES
133	IV IRON
133	ASSUMED
133	EXAMINED
133	HEMODIALYSIS
133	UNITS
133	100
133	IRON SUCROSE
133	INCLUDED
133	WHERE
133	SUCROSE
133	100%
133	IRON
133	USAGE
133	SENSITIVITY
133	COMMUNITY
134	BREAK
134	MAINTAIN
134	COST
134	NEUTRALITY
134	EVEN
134	ESA
134	DOSE REDUCTION
134	REDUCTION
134	CALCULATED
134	DOSE
134	POINT
134	REQUIRED
134	TO MAINTAIN
135	ADULT HD
135	BASELINE
135	95% CONFIDENCE INTERVAL
135	134
135	ACROSS
135	PATIENT
135	IV IRON
135	CONFIDENCE
135	UNITS
135	MONTH
135	764
135	ESA
135	104
135	ADULT
135	118
135	ACTUAL
135	IRON
135	CONFIDENCE INTERVAL
135	DOSE
135	INTERVAL
135	102
136	MEAN
136	COST
136	ESA
136	IV IRON
136	355
136	IRON
136	COMBINED
137	PIVOTAL TRIAL
137	PER YEAR
137	TRIAL
137	USE OF
137	ESTIMATED
137	COMPARISON
137	IV IRON
137	TOTAL
137	325
137	420
137	187
137	ESA
137	USING
137	243
137	REDUCTION
137	923
137	883
137	SAVINGS
137	370
137	COST SAVINGS
137	HIGH
137	IRON
137	USE
137	YEAR
137	SCENARIO
137	MEAN
137	COST
137	215
137	RESULTS
137	DOSE
137	HIGH-DOSE
137	PROGRAM
138	VARIOUS
138	COST
138	CONDITIONS
138	SAVINGS
138	ALTERNATE
138	COST SAVINGS
138	SENSITIVITY ANALYSES
138	POTENTIAL
138	SENSITIVITY
139	COST
139	ESTIMATED
139	NEUTRALITY
139	ESA
139	DOSE REDUCTION
139	REDUCTION
139	10%
139	DOSE
139	IV IRON
139	PROTOCOL
139	HIGH-DOSE
139	REQUIRED
139	HIGH
139	IRON
140	LIMITED
140	ITS
140	RANDOMIZED CONTROLLED TRIAL (RCT)
140	TRIAL
140	USE OF
140	RANDOMIZED
140	DATA
140	ESTIMATE
140	STUDY
140	CONTROLLED TRIAL
140	OUR
140	RANDOMIZED CONTROLLED TRIAL
140	SAVINGS
140	SINGLE
140	COST SAVINGS
140	CONTROLLED
140	USE
140	COST
140	RCT
140	RATHER
141	CONSIDERATION
141	DO NOT
141	HOSPITALIZATIONS
141	OUR
141	COULD BE
141	MODELS
141	DOSE
141	IV IRON
141	ANTICIPATED
141	PROTOCOL
141	TRANSFUSIONS
141	HIGH-DOSE
141	HIGH
141	IRON
141	REDUCTIONS
142	HEMODIALYSIS
142	CANADIAN
142	COST
142	COULD BE
142	DOSE
142	BASED
142	IV IRON
142	PROTOCOL
142	INTEGRATED
142	LARGE
142	REGIONAL
142	HIGH-DOSE
142	COST SAVING
142	HIGH
142	SAVING
142	PROGRAM
142	MODELING
142	IRON
143	TRIAL
143	APPLIED
143	USE
143	DETERMINE
143	SETTING
143	COST
143	PROGRAMS
143	EPO
143	SAVINGS
143	IV IRON
143	PROTOCOL
143	TRIAL PROTOCOL
143	COST SAVINGS
143	REAL
143	WORLD
143	IRON
143	MONITOR
144	PROCESS
144	ETHICAL
144	PAKISTAN
144	COVID-19
144	ETHICAL REVIEW
144	ADAPTING
144	RESEARCH
144	REVIEW
145	RESEARCH ETHICS
145	PROVIDE
145	WAKE
145	TIMELY
145	RESEARCH PROPOSALS
145	COVID-19
145	ETHICS
145	TO PROVIDE
145	GLOBALLY
145	PANDEMIC
145	RESPONSES
145	RESEARCH ETHICS COMMITTEES
145	ADAPTED
145	RESEARCH
145	ETHICS COMMITTEES
145	REVIEWS
145	HAVE
145	COVID-19 PANDEMIC
146	PAKISTAN
146	FOLLOWED
146	REC
146	NATIONAL
146	BIOETHICS
146	COMMITTEE
146	NBC
147	REVIEWED
147	NEWLY
147	PERCEPTIONS
147	COVID-19
147	REC
147	SYSTEM
147	RTR
147	DESCRIBING
147	NBC
147	RESEARCH
147	REVIEW
147	RESEARCH PROPOSALS
147	RAPID
148	DEMOGRAPHIC
148	DATA COLLECTION
148	METHODS
148	MEMBERS
148	QUESTIONNAIRE
148	RESEARCH
148	COLLECTION
148	FILLED
148	USED
148	CROSS
148	INTERVIEWS
148	DATA
148	GROUPS
148	DEPTH
148	REVIEW
148	DOCUMENT
148	RESEARCH PROPOSALS
148	STUDY
148	CROSS-SECTIONAL STUDY
148	CROSS-SECTIONAL
148	PERMANENT
148	QUALITATIVE
148	DOCUMENT 
148	RELATED
148	COVID-19
148	SECTIONAL
149	PERMANENT
149	MEMBERS
150	ESTABLISHED
150	HOURS
150	SYSTEM
150	RTR
150	PROPOSAL
150	72 HOURS
150	TIME
150	REVIEW
151	PROJECTS
151	REVIEWED
151	COMMITTEE
151	MONTHS
152	NUMEROUS
152	STRENGTHS
152	PARTICIPANTS
152	ONLINE
152	JUNIOR
152	INTRODUCTION
152	DESCRIBED
152	NEW
152	SYSTEM
152	DISCUSSIONS
152	ZOOM
152	MEMBERS
152	LEADING
152	LEARNING
152	INCLUDING
152	PRESENCE
152	PRESENCE OF
153	GAIN
153	ENJOYED
153	ALLOWED
153	PREVIOUSLY
153	REC
153	SYSTEM
153	RTR
153	RECOGNITION
153	NBC
154	IDENTIFIED BY
154	CHALLENGES
154	INITIATING
154	DIFFICULTY
154	IDENTIFIED
154	SYSTEM
154	MAY HAVE
154	INCLUDED
154	INITIAL
154	QUALITY
154	RESPONDENTS
154	REVIEW
154	HAVE
155	PROVIDE
155	POOR
155	PRESSURES
155	SCIENTIFIC
155	ADDED
155	TO PROVIDE
155	FRUSTRATIONS
155	COMPOUNDED
155	EXTERNAL
155	QUALITY
155	APPROVAL
155	RAPID
156	PUBLIC HEALTH
156	BEYOND
156	HEALTH EMERGENCY
156	SYSTEM
156	HEALTH
156	RTR
156	EMERGENCY
156	CONSIDERED
156	PUBLIC
157	ADAPTATION
157	ETHICAL
157	TO BE MODIFIED
157	ESSENTIAL
157	MODIFIED
157	PROCESSES
157	EMERGENCIES
157	GUIDELINES 
157	GUIDELINES
157	ETHICAL REVIEW
157	EXISTING
157	NEEDS
157	REVIEW
157	HAVE
159	OBJECTIVES
160	DIET QUALITY
160	TYPE 2
160	OUTCOMES
160	RECONCILIATION
160	QUALITY
160	CLOSE
160	CONSIDERED
160	TRUTH
160	DIABETES
160	TYPE 2 DIABETES
160	IMPORTANT
160	MEDIATOR
160	GAPS
160	ACTION
160	INCLUDING
160	DIET
160	TYPE
160	HEALTH OUTCOMES
160	HEALTH
160	INCLUDES
161	NON
161	STUDY
161	FOOD SECURITY
161	ADULTS
161	COMPARE
161	RESERVE
161	TO COMPARE
161	NON-
161	DIET QUALITY
161	2015
161	PREDICTOR
161	OBJECTIVES
161	2004
161	QUALITY
161	FOOD
161	INDIGENOUS
161	SECURITY
161	DIET
162	METHODS
163	CANADIAN
163	CROSS-SECTIONAL DESIGN
163	CROSS
163	COMMUNITY HEALTH
163	USING
163	2015
163	HEALTH
163	CROSS-SECTIONAL
163	SECTIONAL
163	NUTRITION
163	DESIGN
163	2004
163	COMMUNITY
163	REPEATED
163	HEALTH SURVEYS
163	SURVEYS
163	EMPLOYED
164	POPULATION
164	CANADIAN
164	REPRESENTATIVE
164	PEOPLE
164	INCLUDE
164	LIVING
164	SAMPLE
164	SURVEYS
164	NORTHERN
164	RESERVE
165	NON
165	HEALTHY
165	POPULATION
165	INDIGENOUS
165	TIME
165	VALUES
165	INDIGENOUS POPULATION
165	ESTIMATED
165	NON-
165	PERIOD
165	HOUR
165	HEALTHY EATING INDEX
165	DIETARY
165	USING
165	HEALTHY EATING
165	TIME PERIOD
165	EATING
165	RECALLS
165	INDEX
166	ADJUSTING
166	TO TEST
166	APPLIED
166	TEST
166	GENERALIZED LINEAR MODEL
166	HOUSEHOLD
166	LINEAR
166	TIME
166	LINEAR MODEL
166	ACROSS
166	PERIOD
166	GENERALIZED
166	GROUPS
166	MATCHING
166	FOOD SECURITY
166	MODEL
166	FOOD
166	TIME PERIOD
166	SECURITY
167	RESULTS
168	NON
168	POPULATION
168	MEN
168	CONTINUED
168	INDIGENOUS POPULATION
168	WOMEN
168	NON-
168	COMPARED
168	2015
168	SCORES
168	OVERALL
168	BUT
168	2004
168	INDIGENOUS
168	DIFFERENT
168	LOWER
169	FOOD SECURITY
169	ADULTS
169	FOOD SECURITY STATUS
169	DIET QUALITY
169	STATUS
169	INDEPENDENT OF
169	QUALITY
169	FOOD
169	INDIGENOUS
169	SECURITY
169	INDEPENDENT
169	REPORTED
169	LOWER
169	DIET
170	IMPROVED
170	PERCENT
170	COMPARED
170	FOODS
170	SCORES
170	2015
170	2004
170	ENERGY
171	CONCLUSION
172	NON
172	INDIGENOUS POPULATIONS
172	DISPARITIES
172	NON-
172	DIETARY
172	POPULATIONS
172	INDIGENOUS
173	INDIGENOUS POPULATIONS
173	DIET QUALITY
173	HOUSEHOLD
173	ADDRESSING
173	INDIGENOUS
173	NECESSARY
173	SUFFICIENT
173	FOOD
173	POPULATIONS
173	QUALITY
173	INSECURITY
173	FOOD INSECURITY
173	DIET
174	VARIABILITY
174	BIOPSY
174	PROSTATE BIOPSY
174	INEFFICIENCY
174	PROSTATE
174	IS A
174	RATE
174	POST
174	VOIDING
174	REPORTED
175	BURDEN
175	MORBIDITY
175	NOT WELL
175	AFRICAN
175	POTENTIAL
175	PATIENTS
176	TRANS-RECTAL
176	STUDY
176	POPULATION
176	RECTAL
176	INCIDENCE
176	CLINICAL
176	FUNCTION
176	PROSTATE BIOPSY
176	BIOPSY
176	AFFECTING
176	TRANS
176	PATIENTS
176	PROSTATE
176	AFRICAN
176	HISTOLOGICAL
176	VOIDING
176	EVALUATE
177	TRANS-RECTAL
177	YEARS
177	CARRIED
177	PROSTATE
177	SCHEDULED
177	SUSPECTED PROSTATE CANCER
177	BIOPSY
177	PROSTATE CANCER
177	PROSTATE BIOPSY
177	COHORT STUDY
177	STUDY
177	CANCER
177	OBSERVATIONAL COHORT STUDY
177	TRANS
177	OBSERVATIONAL
177	ADULT
177	COHORT
177	SUSPECTED
177	RECTAL
177	MALES
178	NEUROLOGICAL
178	EITHER
178	DRUGS
178	EXCLUDED
178	AFFECT
178	CONDITIONS
178	NEUROLOGICAL CONDITIONS
178	SPONTANEOUSLY
178	VOID
178	RESEARCH
178	VOIDING
179	DEMOGRAPHIC
179	CHARACTERISTICS
179	DEMOGRAPHIC CHARACTERISTICS
179	DATA
179	COLLECTED
179	PATIENTS
180	URINE FLOW
180	PEAK
180	URINE
180	PROCEDURE
180	THE PEAK
180	SEVEN
180	DAYS
180	UROFLOWMETRY
180	FLOW
180	BASELINE
180	RATE
180	FLOW RATE
180	PATIENTS
180	OBTAIN
181	PROSTATE VOLUME
181	DETERMINED
181	RISK
181	CLINICAL
181	RECORDED
181	RISK FACTORS
181	VOLUME
181	PROSTATE
181	HISTOLOGICAL
181	POTENTIAL
181	PRESENCE
181	PRESENCE OF
182	PRESENCE
182	RELATED
182	RECORDED
182	COMPLICATIONS
182	BLEEDING
182	BIOPSY
182	BIOPSY COMPLICATIONS
182	PRESENCE OF
183	ANALYSIS
183	SPSS
183	STATISTICAL
183	LESS THAN
183	USING
183	P-VALUE
183	SIGNIFICANT
183	LESS THAN 0.05
183	STATISTICAL ANALYSIS
183	0.05
183	VALUE
183	REPORTED
184	SEVENTH
184	PEAK FLOW
184	PEAK
184	VALUES
184	RECORDED
184	INEFFICIENCY
184	MAJORITY
184	DECREASE
184	RATE
184	POINT
184	FLOW RATE
184	PEAK FLOW RATE
184	VOIDING
184	PATIENTS
184	FLOW
184	DAY
185	OCCURRED
185	POPULATION
185	HAEMATURIA
185	POST
185	BIOPSY
186	TIMES
186	PROCEDURE
186	RISK
186	HAEMATURIA
186	BLOOD CLOTS
186	PRESENCE
186	ASSOCIATED
186	INCREASED RISK
186	RISK OF
186	INEFFICIENCY
186	CLOTS
186	ASSOCIATED WITH
186	10.9
186	INCREASED
186	VOIDING
186	BLOOD
186	PRESENCE OF
187	ABOUT
187	BIOPSY
187	PROSTATE BIOPSY
187	INEFFICIENCY
187	PROSTATE
187	POST
187	VOIDING
187	PATIENTS
188	MORBIDITY
188	ASSOCIATED
188	BLOOD CLOT
188	CLOT
188	ASSOCIATED WITH
188	BLOOD
188	OCCURRENCE
188	PRESENCE
189	KEYWORDS
190	RISK FACTOR
190	FACTOR
190	RISK
190	TRACT
190	PROSTATE BIOPSY
190	URINARY
190	URINARY TRACT
190	LOWER URINARY TRACT SYMPTOMS
190	URINARY RETENTION
190	LOWER URINARY TRACT
190	PROSTATE
190	RETENTION
190	BIOPSY
190	LOWER
190	SYMPTOMS
191	SEPTIC
191	MEDICAL EMERGENCY
191	SEPTIC ARTHRITIS
191	ARTHRITIS
191	CONSIDERED
191	MEDICAL
191	EMERGENCY
192	BACTERIAL COLONIZATION
192	MORBIDITY
192	MORBIDITY AND MORTALITY
192	REQUIRES
192	SIGNIFICANT
192	MORTALITY
192	BACTERIAL
192	TREATMENT
192	FOLLOWING
192	COLONIZATION
192	LEAD
192	DISEASE
193	PROPERTIES
193	STROMAL CELLS
193	REGENERATIVE
193	MESENCHYMAL STROMAL CELLS
193	STROMAL
193	MEDICINE
193	HUMAN
193	ANTIMICROBIAL
193	THERAPIES
193	RESEARCHED
193	CELLS
193	PLATELET
193	REGENERATIVE THERAPIES
193	INCLUDING
193	HAVE
193	MESENCHYMAL
194	FEWER
194	SPECIES
194	VETERINARY
194	RESULTS
194	STUDIES
194	HAVE
195	PURPOSE
195	STROMAL
195	ESCHERICHIA
195	BACTERIAL
195	HORSES
195	ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS
195	LYSATE
195	STAPHYLOCOCCUS
195	MESENCHYMAL STROMAL CELLS
195	SUPPRESSION
195	USED
195	STAPHYLOCOCCUS AUREUS
195	STAPHYLOCOCCUS 
195	PLATELET LYSATE
195	MESENCHYMAL
195	ESCHERICHIA COLI
195	STUDY
195	STROMAL CELLS
195	POOLED
195	EQUINE
195	CELLS
195	PLATELET
195	IN VITRO
195	EVALUATE
195	PRODUCTION
195	GROWTH
195	ADIPOSE
195	DERIVED
195	EPL
195	BLOOD
196	GLUTEAL REGION
196	STROMAL CELLS
196	MESENCHYMAL STROMAL CELLS
196	STROMAL
196	GLUTEAL
196	ADIPOSE TISSUE
196	TISSUE
196	ADIPOSE
196	REGION
196	CELLS
196	ISOLATED
196	HORSES
196	MESENCHYMAL
197	STUDY
197	EVALUATED
197	1.6
197	CONTROL
197	REPEATED MEASUREMENTS
197	UNBALANCED
197	USING
197	MILLION
197	INCOMPLETE
197	TREATMENT
197	DESIGN
197	MEASUREMENTS
197	REPEATED
197	BLOCK
197	GROUPS
197	BLOCK DESIGN
197	EPL
198	COLONY-FORMING UNITS
198	READINGS
198	UNITS
198	HOURS
198	FORMING
198	COLONY
198	CALCULATED
198	OPTICAL DENSITY
198	COLONY-FORMING
198	24 HOURS
198	OPTICAL
198	DENSITY
199	HYPOTHESIS
199	DECREASED
199	BACTERIAL GROWTH
199	OUR
199	SEEN
199	POINTS
199	S. AUREUS
199	BACTERIAL
199	GROWTH
199	ASC
199	SUPPORTING
199	TIME
199	EPL
199	TREATMENTS
199	MULTIPLE
200	HYPOTHESIS
200	E. COLI
200	GROUP
200	BACTERIAL GROWTH
200	NO DIFFERENCE
200	OUR
200	DIFFERENCE
200	BACTERIAL
200	GROWTH
200	ASC
200	TREATMENT
200	INCREASED
200	EPL
201	STUDY
201	CLEAR
201	CONCLUSION
201	ANTIMICROBIAL
201	EFFECTS
201	IN VITRO
201	EPL
202	NEEDED
202	BACTERIA
202	SIGNIFICANT
202	GRAM-POSITIVE
202	BACTERIA.
202	POSITIVE
202	S. AUREUS
202	GROWTH
202	DECREASING
202	THESE
202	STUDIES
202	GRAM
202	HAVE
202	GRAM-
202	GRAM-POSITIVE BACTERIA
202	EFFECT
203	PROFESSOR
203	APPROACH
203	INTERESTS
203	GLOBAL
203	ARCHAEOLOGIST
203	NORWEGIAN
203	RESEARCH
203	IS A
204	YEARS
204	FUR
204	CONVERSATION
204	CAPACITY
204	SUPPORT
204	RESEARCH
204	EXPERIENCE
204	AFRICA
204	WOMAN
204	DEVELOPMENT
204	MULTIFACETED
204	PROGRAMS
204	ARCHAEOLOGY
204	PARADIGMS
204	COOPERATION
204	MID
204	NORWEGIAN
204	BUILDING
204	POST
204	YOUNG
204	NORAD
204	ENGAGEMENT
204	SUDAN
204	PROCESSUAL
204	REFLECTS
204	AGENCY
205	AFRICA
205	ARCHAEOLOGY
205	CREATED
205	UNIQUE
205	PATH
206	INTERVIEW
206	NOVEL
206	UNDERSTANDING
206	FOOD CULTURE
206	GENDER
206	HUMAN
206	BEGINNINGS
206	PAST
206	CULTURE
206	RIGHT
206	FOOD
206	TECHNOLOGY
206	DEPTH
206	PATH
206	PRODUCTION
208	BACKGROUND
209	BREAST
209	TO CONTROL
209	CONTROL
209	CANCER SURGERY
209	OPTIMAL
209	TECHNIQUE
209	CANCER
209	PAIN AFTER
209	SURGERY
209	REGIONAL
209	CONTROL PAIN
209	PAIN
209	REMAINS
209	UNCLEAR
209	BREAST CANCER
210	BREAST
210	MAJOR
210	OUTCOMES
210	CONTROLLED TRIALS
210	RANDOMIZED
210	DATA
210	REGIONAL
210	TECHNIQUES
210	FOLLOWING
210	TRIALS
210	COMPARING
210	VARIOUS
210	SURGERY
210	SYNTHESIZE
210	CONTROLLED
210	AVAILABLE
210	RELATED
210	BREAST SURGERY
210	RANDOMIZED CONTROLLED TRIALS
210	ONCOLOGIC
210	PAIN
211	METHODS
212	META
212	MEDLINE
212	SEARCHED
212	EMBASE
212	JULY
212	SCOPUS
212	2020
212	META-ANALYSIS
212	USED
212	REGIONAL
212	TECHNIQUES
212	TRIALS
212	REVIEW
212	ANALYSIS
212	NETWORK
212	SCHOLAR
212	SYSTEMATIC REVIEW
212	NETWORK META-ANALYSIS
212	GOOGLE
212	CENTRAL
212	PUBMED
213	OUTCOME
213	SCORE
213	PRIMARY
213	NUMERICAL
213	RESTING
213	PAIN SCORE
213	PAIN
213	PRIMARY OUTCOME
213	MEASURED
213	RATING
214	CUMULATIVE
214	SURFACE
214	ESTABLISH
214	USED
214	SUCRA
214	INTERVENTION
214	CURVE
214	PROBABILITY OF
214	RANKING
214	PROBABILITY
214	HIGHEST
215	ANALYSIS
215	MODEL
215	CRL
215	SIZES
215	USING
215	PERFORMED
215	CREDIBLE INTERVAL
215	EFFECTS
215	INTERVAL
215	RANDOM EFFECTS MODEL
215	EFFECT SIZES
215	RANDOM
215	95% CREDIBLE INTERVAL
215	REPORTED
215	EFFECT
216	ANALYSIS
216	POSTOPERATIVE
216	CLUSTER
216	OPIOID USE
216	USE
216	NAUSEA
216	RANK
216	VOMITING
216	INCIDENCE
216	POSTOPERATIVE NAUSEA AND VOMITING
216	POSTOPERATIVE NAUSEA
216	NAUSEA AND VOMITING
216	PAIN
216	OPIOID
216	RANKING
216	COMBINING
217	RESULTS
218	SEVENTY-NINE
218	RANDOMIZED
218	686
218	CONTAINING
218	SEVENTY
218	RANDOMIZED CONTROLLED TRIALS
218	INTERVENTIONS
218	CONTROLLED
218	INCLUDED
218	DIFFERENT
218	CONTROLLED TRIALS
218	TRIALS
218	PATIENTS
219	SUCRA
219	SERRATUS
219	WOUND
219	RESTING
219	ERECTOR SPINAE
219	PAIN SCORE
219	PARAVERTEBRAL
219	SERRATUS ANTERIOR PLANE BLOCK
219	0.68
219	0.45
219	PARAVERTEBRAL BLOCK
219	VALUES
219	ANTERIOR PLANE
219	PLANE
219	LEVEL
219	BLOCK
219	INTERCOSTAL
219	MODIFIED
219	ANTERIOR
219	PLACEBO
219	SCORE
219	SINGLE
219	INTERVENTIONS
219	0.59
219	SERRATUS ANTERIOR
219	0.12
219	0.08
219	INFUSION
219	PECTORAL
219	WOUND INFILTRATION
219	INTERVENTION
219	CONTINUOUS
219	0.33
219	INFILTRATION
219	PAIN
220	SERRATUS
220	DIFFERENCE
220	RESTING
220	PARAVERTEBRAL
220	SERRATUS ANTERIOR PLANE BLOCK
220	PARAVERTEBRAL BLOCK
220	ANTERIOR PLANE
220	CRL
220	ESTIMATED
220	PLANE
220	0.32
220	SCORES
220	BLOCK
220	PROBABILITY
220	ANTERIOR
220	PLACEBO
220	COMPARED
220	PROBABILITY OF
220	PAIN SCORES
220	SERRATUS ANTERIOR
220	1.9
220	MEAN
220	CONTINUOUS
220	DECREASING
220	PAIN
220	1.26
220	MEAN DIFFERENCE
220	HIGHEST
221	ANALYSIS
221	CLUSTER
221	OPIOID USE
221	USE
221	ANALGESIA
221	EFFECTIVE
221	INTERVENTION
221	PLACEBO
221	RESTING
221	SCORES
221	PAIN SCORES
221	REGIONAL
221	TECHNIQUES
221	PAIN
221	OPIOID
221	RANKING
221	COMBINING
222	REDUCING
222	NAUSEA AND VOMITING
222	INFUSION
222	POSTOPERATIVE
222	VOMITING
222	NAUSEA
222	WOUND INFILTRATION
222	WOUND
222	ACTIVE
222	CONTINUOUS
222	POSTOPERATIVE NAUSEA AND VOMITING
222	INTERVENTIONS
222	INFILTRATION
222	MAY BE
222	POSTOPERATIVE NAUSEA
222	EFFECTIVE
223	CONCLUSION
224	BREAST
224	SERRATUS
224	MAJOR
224	PARAVERTEBRAL
224	SERRATUS ANTERIOR PLANE BLOCK
224	PARAVERTEBRAL BLOCK
224	REDUCING
224	ANTERIOR PLANE
224	PLANE
224	BLOCK
224	PROBABILITY
224	ANTERIOR
224	SURGERY
224	PROBABILITY OF
224	HIGH
224	SERRATUS ANTERIOR
224	HIGH PROBABILITY
224	CONTINUOUS
224	BREAST SURGERY
224	ONCOLOGIC
224	PAIN
225	MODERATE
225	CERTAINTY
225	VERY LOW
225	EVIDENCE
225	OF EVIDENCE
225	LOW
226	SURGEON
226	ANESTHESIA
226	WOUND INFILTRATION
226	COMPARE
226	CATHETERS
226	WOUND
226	FUTURE
226	REGIONAL
226	TECHNIQUES
226	ADMINISTERED
226	STUDIES
226	INFILTRATION
226	DIFFERENT
226	REGIONAL ANESTHESIA
226	INCLUDING
227	COMPARING
227	TO CHANGE
227	CHANGE
227	PRACTICE
227	INTERVENTION
227	PLACEBO
227	ACTIVE
227	CLINICAL PRACTICE
227	CLINICAL
227	TRIALS
227	UNLIKELY
228	STUDY
228	REGISTRATION
229	INTRAOPERATIVE
229	ABOUT
229	PERFORMANCE
229	SURGICAL
229	REMAINS
229	TRAINING
229	FEEDBACK
230	METHOD
230	SURGICAL
230	VIDEO
230	POTENTIAL
230	EFFECTIVE
230	FEEDBACK
231	METHOD
231	BETTER
231	RESEARCH
231	NEEDED
231	UNDERSTAND
232	STUDY
232	OPERATING ROOM
232	NATURE
232	GYNECOLOGY
232	USING
232	POST-OPERATIVE
232	ROOM
232	OBGYN
232	OBSTETRICS
232	INTERACTIONS
232	VIDEO
232	TRAINING
232	OPERATIVE
232	OBSTETRICS AND GYNECOLOGY
232	POST
232	OPERATING
232	REVIEW
232	FEEDBACK
233	CASE STUDY
233	STUDY
233	SEPTEMBER
233	OCCURRED
233	2016
233	FEBRUARY
233	CASE
233	2017
234	SUPERVISING
234	SURGEONS
234	CASES
234	LAPAROSCOPIC
234	OBGYN
234	INVOLVED
235	ANALYSIS
235	INTRAOPERATIVE
235	PUBLISHED
235	RECORDED
235	USING
235	CODES
235	IDENTIFIED
235	DATA
235	VIDEO
235	LITERATURE
236	INTRAOPERATIVE
236	376
236	IDENTIFIED
236	INTERACTIONS
236	DIALOGUE
236	MINUTES
237	PERFORM
237	HOW
237	USE
237	RESIDENT
237	TASK
237	INSTRUCTING
237	INSTRUMENT
237	INTERACTIONS
238	ANALYSIS
238	POSTOPERATIVE
238	IDENTIFIED
238	INTERACTIONS
238	VIDEO
238	REVIEW
238	MINUTES
239	INTERACTION
239	COMPONENT
239	TYPE
239	TEACHING
239	INTERACTION TYPE
239	INCLUDED
239	COMMON
239	MORE OFTEN
240	APPARENT
240	ANALYSIS
240	FOCUS
240	INTRAOPERATIVE
240	CAPTURE
240	NATURE
240	USING
240	CODES
240	VIDEO
240	FEEDBACK
240	DID
241	ANALYSIS
241	RESIDENT
241	IDENTIFIED
241	VIDEO
241	REFLECTION
241	HERMENEUTIC
242	STUDY
242	GREATER
242	NATURE
242	IMPROVED
242	COLLABORATIVE
242	VIDEO
242	DIFFERENT
242	POTENTIAL
242	IMPROVED LEARNING
242	FEEDBACK
242	OFFERING
242	LEARNING
243	YEARS
243	COMPARATIVE
243	EARLY
243	CHILDHOOD DEVELOPMENT
243	AGED
243	EARLY CHILDHOOD
243	COMPARATIVE STUDY
243	COSTA RICA
243	CHILDREN
243	DEVELOPMENT
243	EARLY CHILDHOOD DEVELOPMENT
243	CHILDHOOD
243	STUDY
243	COSTA
243	GHANA
243	BANGLADESH
243	DETERMINANTS
243	5 YEARS
243	INDEX
244	LATER
244	FACTOR
244	CHILDREN
244	DEVELOPMENT
244	BEING
244	EARLY
244	LATER LIFE
244	HEALTH
244	WELL-BEING
244	LIFE
244	CHILD DEVELOPMENT
244	CHILD
244	CONTROLS
244	IS A
245	YEARS
245	CHILDREN
245	DEVELOPMENT
245	DETERMINE
245	EARLY
245	INFLUENCE
245	SOCIODEMOGRAPHIC
245	SOCIODEMOGRAPHIC FACTORS
245	CHILD DEVELOPMENT
245	AGED
245	CHILD
245	5 YEARS
245	INDEX
246	2019
246	2017
246	CLUSTER
246	COSTA RICA
246	CROSS
246	DATA
246	PERFORMED
246	2018
246	MULTIPLE
246	ANALYSIS
246	SURVEY DATA
246	USING
246	CROSS-SECTIONAL
246	INDICATOR
246	COSTA
246	SURVEYS
246	CROSS-SECTIONAL SURVEY
246	SURVEY
246	BANGLADESH
246	GHANA
246	SECTIONAL
247	ANALYSIS
247	BIVARIATE ANALYSIS
247	COUNTRIES
247	TEST
247	BIVARIATE
247	USED
247	MODEL
247	SUP
247	REGRESSION
247	LOGISTIC
247	MULTIVARIATE ANALYSIS
247	ALL 3
247	BINARY
247	REGRESSION MODEL
247	LOGISTIC REGRESSION
247	LOGISTIC REGRESSION MODEL
248	SPSS
248	VERSION
248	STATISTICAL
248	0.0
248	PERFORMED
248	IBM
248	STATISTICAL ANALYSES
249	EDUCATION
249	CHILD AGE
249	FUNCTIONAL
249	SEX
249	CHILD
249	ECONOMIC
249	EDUCATION LEVEL
249	DIFFICULTIES
249	GREATEST
249	CHILDREN
249	LEVEL
249	NUTRITIONAL STATUS
249	STATUS
249	READING
249	NUTRITIONAL
249	MATERNAL
249	ECONOMIC STATUS
249	EFFECT
249	FOLLOWED
249	AGE
249	BOOKS
249	FOLLOWED BY
250	ODDS
250	CHILDREN
250	DEVELOPMENT
250	GIRLS
250	BANGLADESH
250	COSTA RICA
250	BOYS
250	GHANA
250	AGED
250	COSTA
250	MONTHS
250	LOWER
251	ODDS
251	CHILDREN
251	DEVELOPMENT
251	COSTA RICA
251	GHANA
251	RURAL
251	BUT
251	HIGHER
251	URBAN
251	COSTA
251	LOWER
252	EDUCATION
252	ECONOMIC CONDITIONS
252	EARLY
252	IMPROVING
252	ENHANCE
252	ECONOMIC
252	COUNTRIES
252	CHILDREN
252	DEVELOPMENT
252	CONDITIONS
252	NECESSARY
252	NUTRITION
252	GOVERNMENTS
252	RECOMMEND
252	STEPS
252	ALL 3
252	BALANCED
252	BEING
252	WELL-BEING
252	PROVIDING
253	INTERGENERATIONAL
253	COVID-19
253	EVIDENCE
253	EFFECTIVENESS
253	PANDEMIC
253	IMPLEMENTATION
253	LEARNING
253	CHINA
253	COVID-19 PANDEMIC
254	GRANDCHILDREN
254	USED
254	COVID-19
254	GRANDPARENTS
254	PANDEMIC
254	TIME
254	CHINA
254	HAVE
254	COVID-19 PANDEMIC
255	ONLINE
255	ROLES
255	ADULT CHILDREN
255	HOUSEHOLD
255	RETURNED TO WORK
255	TAKING
255	LOOKING
255	SUPPORT
255	LEARNING
255	ACADEMIC
255	CHILDREN
255	ONLINE LEARNING
255	GRANDPARENTS
255	PERIOD
255	RETURNED
255	CARE
255	CARE OF
255	SUPERVISING
255	BASIC
255	LOCKDOWN
255	EXTENDED
255	ADULT
255	NEEDS
255	WORK
255	GRANDCHILDREN
255	HOUSEHOLD TASKS
255	PROVIDING
256	CHILDREN
256	OPPORTUNITY
256	OTHER.
256	BETTER
256	GRANDPARENTS
256	LEARN
257	EDUCATION
257	INTERGENERATIONAL
257	STUDENTS
257	PRIMARY
257	INSTITUTE
257	CHINESE
257	LEARNING
257	INVESTIGATED
257	SCHOOLS
257	ACROSS
257	GRANDPARENTS
257	PERIOD
257	SEVEN
257	LIFE PROJECT
257	VACATION
257	LOCATED IN
257	CHINA
257	LED
257	EAST
257	PROJECT
257	MONTH
257	MUNICIPAL
257	PRIMARY SCHOOLS
257	SMILE
257	INITIATIVE
257	LIFE
257	UNIVERSITY
257	GRANDCHILDREN
257	SHAPING
257	AREAS
257	HOME
257	NORMAL
257	IL-
258	LITERACY
258	PANDEMIC
258	PREVENTION
258	HEALTH
258	CULTURE
258	TRADITIONAL
258	INFORMATION
258	INFORMATION LITERACY
258	FITNESS
259	AUTHORS
259	HOW
259	INQUIRY
259	SCHOOLS
259	PROJECT
259	PRIMARY SCHOOLS
259	PRIMARY
259	IMPACT
259	IMPLEMENTED
259	FOLLOWING
259	IL-
259	ITS
259	PARTICIPATING
259	UNDERSTAND
259	ARTICLE
260	GENERATION
260	FAMILIES
260	BEHAVIOURS
260	CONCEPT
260	BASED
260	AGED
260	UNDERSTOOD
260	MAIN
260	KNOWLEDGE
260	LEARNING
260	VALUES
260	PERSPECTIVE
260	INTERVIEWS
260	GRANDPARENTS
260	TEACHERS
260	LIFE SKILLS
260	RELATIONSHIPS
260	YOUNGER
260	GAINED
260	SKILLS
260	DEPTH
260	LIFELONG LEARNING
260	LIFE
260	GENERATIONS
260	CHANGED
260	INCLUDING
260	GRANDCHILDREN
260	OLDER
260	HEALTH
260	FINDINGS
260	HEALTH KNOWLEDGE
262	PURPOSE
263	REACH
263	INTENSIVE CARE
263	UNITS
263	ICUS
263	COVID-19
263	TRIAGE
263	PANDEMIC
263	CARE
263	CAUSED
263	COVID-19 PANDEMIC
263	INTENSIVE CARE UNITS
264	POPULATION
264	TOOL
264	PATIENTS
264	ACROSS
264	INFORM
264	MORTALITY
264	LEVEL
264	VENTILATED
264	RESOURCE
264	RESOURCE ALLOCATION
264	MORTALITY RISK
264	ALLOCATION
264	DECISION-MAKING
264	PREDICT
264	RISK
264	COVID-19
264	ALLOW
264	INSTITUTIONS
264	DECISION
265	METHODS
266	ADULTS
266	DECEMBER
266	2020
266	TERTIARY CARE
266	ADMITTED
266	CARE
266	VENTILATED
266	TORONTO
266	COHORT STUDY
266	STUDY
266	RETROSPECTIVE
266	RETROSPECTIVE COHORT STUDY
266	ONTARIO
266	MARCH
266	INCLUDED
266	COHORT
266	ICUS
266	COVID-19
266	ADMITTED TO
266	TERTIARY
267	EQUATIONS
267	USED
267	TO IDENTIFY
267	VARIABLES
267	ESTIMATING EQUATIONS
267	PREDICTIVE
267	MORTALITY
267	GENERALIZED
267	IDENTIFY
267	ESTIMATING
268	PRIMARY
268	DAYS
268	ICU
268	TIME
268	EVERY THREE DAYS
268	OUTCOME
268	ESTIMATED
268	FINAL
268	PROBABILITY
268	CALCULATION
268	INTERVALS
268	ICU ADMISSION
268	ADMISSION
268	PROBABILITY OF
268	PRIMARY OUTCOME
268	RISK
268	BEYOND
268	DEATH
268	DAY
269	MODEL
269	NUMERICAL ALGORITHM
269	FINAL
269	NUMERICAL
269	ALGORITHM
269	COEFFICIENTS
270	RESULTS
271	TWENTY
271	ELIGIBLE
271	SEVEN
271	ONE HUNDRED TWENTY
271	INCLUSION
271	ONE HUNDRED
271	PATIENTS
271	TWENTY-SEVEN
272	RANGE
272	15.4
272	LENGTH OF STAY
272	MEDIAN
272	DAYS
272	ICU
272	INTERQUARTILE RANGE
272	LENGTH
273	OVERALL MORTALITY
273	MORTALITY
273	OVERALL
274	TIDAL
274	VASOPRESSOR
274	USE
274	PREDICTED
274	VARIABLES
274	VENTILATION
274	LACTATE LEVEL
274	AGE
274	LEVEL
274	TEMPERATURE
274	VOLUME
274	MORTALITY
274	LACTATE
274	TIDAL VOLUME
274	DAY
275	CONFIDENCE
275	CONFIDENCE INTERVAL
275	CHARACTERISTICS
275	RISK
275	0.8
275	0.9
275	CLINICAL
275	OUR
275	FINAL
275	SCORE
275	AREA
275	CURVE
275	INTERVAL
275	CLINICAL RISK
275	95% CONFIDENCE INTERVAL
275	RECEIVER
275	OPERATING
275	RISK SCORE
276	INCREASE IN RISK
276	ODDS
276	RATIO
276	RISK
276	APPROXIMATELY
276	SCORE
276	RELATIVE
276	ODDS RATIO
276	2.9
276	DEATH
276	4.1
276	POINT
276	INCREASE
276	RISK SCORE
277	CONCLUSION
278	PROPERTIES
278	DYNAMIC
278	PREDICTION
278	OUR
278	COVID-19
278	MORTALITY
278	EXCELLENT
278	TOOL
278	VENTILATED
278	DIAGNOSTIC
278	PATIENTS
279	BACKGROUND
280	TESTING
280	HYPERADRENOCORTICISM
280	USE OF
280	USE
280	DERMATOLOGICAL DISEASE
280	SUPPRESSION
280	OTIC PREPARATIONS
280	DOGS
280	TOPICAL CORTICOSTEROIDS
280	TOPICAL
280	FOLLOWING
280	ADRENOCORTICAL
280	CORTICOSTEROIDS
280	ADULT
280	DOCUMENTED
280	OTIC
280	DERMATOLOGICAL
280	DISEASE
281	APPLICATION
281	CONTAINS
281	USED
281	CANINE
281	OTITIS EXTERNA
281	SUSPENSION
281	MOMETASONE
281	OTITIS
281	SINGLE
281	OTIC SUSPENSION
281	MOMETASONE FUROATE
281	TREAT
281	FREQUENTLY
281	FLORFENICOL
281	FUROATE
281	TERBINAFINE
281	OTIC
282	TWO WEEKS
282	SUPPRESSION
282	CAUSE
282	WEEKS
282	APPLICATIONS
282	MEDICATION
282	ADRENOCORTICAL
282	APART
282	DAY
283	HYPOTHESIS
283	OBJECTIVES
284	BREED
284	STUDY
284	HEALTHY
284	OBJECTIVE
284	DETERMINE
284	SUPPRESSION
284	BILATERAL
284	DOGS
284	MOMETASONE
284	TOPICAL
284	D28
284	SMALL
284	MOMETASONE FUROATE
284	ADRENOCORTICAL
284	FLORFENICOL
284	FUROATE
284	CAUSES
284	TERBINAFINE
285	ANIMAL
286	NON
286	PSEUDOMONAS
286	WEIGHING
286	NON-
286	DOGS
286	BILATERAL
286	SEVEN
286	DIAGNOSED
286	CLIENT
287	METHODS
287	MATERIALS
288	ACTH
288	CORTISOL
288	PRE
288	POST
288	MEASURED
288	STIMULATION
289	APPLIED
289	MOMETASONE
289	TOPICAL
289	BOTH EARS
289	MOMETASONE FUROATE
289	EARS
289	FLORFENICOL
289	FUROATE
289	TERBINAFINE
290	DOGS
290	ACTH
290	CORTISOL
290	D28
290	PRE
290	POST
290	MEASURED
290	STIMULATION
291	RESULTS
292	RANGE
292	CONCENTRATIONS
292	ACTH
292	5-23
292	MEDIAN
292	CORTISOL
292	D28
292	2.0
292	11.5
292	PRE
292	RANGE 2
292	POST
293	CONCENTRATIONS
293	ACTH
293	CORTISOL
293	SIGNIFICANT
293	DIFFERENCE
293	D28
293	POST
294	CONCLUSIONS
294	CLINICAL RELEVANCE
294	RELEVANCE
294	CLINICAL
295	TESTING
295	APPLIED
295	FUNCTION
295	NO EVIDENCE OF
295	NEED
295	MOMETASONE
295	TOPICAL
295	MOMETASONE FUROATE
295	ADRENOCORTICAL
295	EVIDENCE OF
295	FUROATE
295	DELAY
295	SUPPRESSION
295	MANUFACTURER
295	DOGS
295	EVIDENCE
295	TREATED WITH
295	DEMONSTRATED
295	TREATED
295	FLORFENICOL
295	TERBINAFINE
295	RECOMMENDATIONS
295	RESULTS
296	UPPER LIMB
296	PROCEDURE
296	LIMB
296	LIMB SURGERY
296	IS A
296	INVOLVED
296	BRACHIAL PLEXUS BLOCKADE
296	SURGEONS
296	BRACHIAL PLEXUS
296	POPULARITY
296	SURGERY
296	PLEXUS
296	BPB
296	UPPER
296	ANAESTHESIOLOGISTS
296	BLOCKADE
296	BRACHIAL
296	UPPER LIMB SURGERY
296	GROWING
297	BENEFIT
297	SURGERY
297	HAND SURGERY
297	HAND
297	SAFETY
297	UNCLEAR
298	YEAR
298	CHART REVIEW
298	RETROSPECTIVE
298	PERFORMED
298	CASES
298	PERIOD
298	HAND
298	EXAMINING
298	CHART
298	REVIEW
298	OPERATIVE
299	INTERNAL
299	LOC
299	PROCEDURES
299	PAEDIATRIC
299	OPEN
299	OPEN REDUCTION
299	ADDITIONAL
299	REDUCTION INTERNAL
299	PATIENT
299	PERFORMED
299	EXCLUDED
299	INTERNAL FIXATION
299	AND/OR
299	CASES
299	REDUCTION
299	METACARPAL
299	INCLUDED
299	FIXATION
299	DECREASED
299	OPEN REDUCTION INTERNAL FIXATION (ORIF)
299	OPEN REDUCTION INTERNAL FIXATION
299	ORIF
299	PROCEDURES PERFORMED
300	STATISTICAL
300	STATISTICAL TESTS
300	PERFORMED
300	TESTS
300	PARAMETRIC STATISTICAL TESTS
301	BPB
301	STUDY
301	GENERAL ANAESTHESIA
301	ANAESTHESIA
301	CASES
301	IDENTIFIED
301	GENERAL
301	TOTAL
301	102
302	BPB
302	AVERAGE
302	GROUP
302	DISCHARGE
302	001
302	OPERATING THEATRE
302	TOTAL
302	THEATRE
302	245
302	TIME
302	OPERATING
302	195
302	MINUTES
303	BPB
303	ANALGESIA
303	001
303	POST
303	REQUIRED
303	VERSUS
303	PATIENTS
304	BPB
304	ANTI-EMETICS
304	EMETICS
304	001
304	POST
304	REQUIRED
304	GROUPS
304	PATIENTS
305	DIFFERENT
305	PARENTERAL
305	NEED
305	MEDICATION
305	POST
305	NEED FOR
305	001
306	BPB
306	STUDY
306	ANAESTHETIC
306	ESTABLISHING
306	METHOD
306	EFFICIENT
306	SAFE
306	ADDING
306	ANAESTHESIA
306	BODY
306	HAND
306	TECHNIQUES
306	FRACTURES
306	ORIF
306	LITERATURE
308	BACKGROUND
309	ENHANCEMENT
309	TESTOSTERONE
309	LIKE
309	PERFORMANCE
309	ROLE
309	PLAY
309	GROWTH
309	MUSCLE
309	HORMONES
309	PERFORMANCE ENHANCEMENT
310	CONTEXT
310	TO INCREASE
310	VARIOUS
310	CONCENTRATION
310	TESTOSTERONE
310	RESISTANCE TRAINING
310	RESISTANCE
310	INCREASE
310	TRAINING
310	RELEASE
310	HAVE
311	RESULT
311	PROMOTE
311	ACTIVITY
311	CONCENTRATION
311	COITUS
311	HOURS
311	SEXUAL
311	TESTOSTERONE
311	MASTURBATION
311	SEXUAL ACTIVITY
311	PRACTITIONERS
311	INCREASES
311	MUSCLE
311	GROWTH
311	FEW HOURS
311	TRAINING
312	INVESTIGATED
312	KINETICS
312	ACTIVITY
312	TESTOSTERONE
312	SEXUAL
312	EVIDENCE
312	CORTISOL
312	SEXUAL ACTIVITY
312	ASSUMPTION
312	SUPPORT
312	RESPONSE
312	TO SUPPORT
312	HAVE
313	STUDY
313	HORMONE
313	PILOT
313	RATIOS
313	KINETICS
313	CONCENTRATIONS
313	TESTOSTERONE, FREE
313	TESTOSTERONE
313	CORTISOL
313	MASTURBATION
313	FREE TESTOSTERONE
313	TOTAL TESTOSTERONE
313	AIM
313	TOTAL
313	TO EXAMINE
313	FREE
314	VISUAL
314	STUDY
314	HEALTHY
314	MEN
314	KINETICS
314	CROSS
314	COMPARED
314	MASTURBATION
314	STIMULUS
314	SINGLE
314	YOUNG
314	EFFECTS
314	CROSS-OVER
314	BLINDED
314	NATURAL
314	ARM
314	CROSS-OVER STUDY
314	VISUAL STIMULUS
315	RESULTS
316	CONCENTRATIONS
316	TESTOSTERONE
316	SIGNIFICANT
316	DIFFERENCE
316	RESULTS
316	CONDITION
316	FREE TESTOSTERONE
316	FREE
317	0.01
317	VISUAL
317	CONCENTRATIONS
317	TESTOSTERONE
317	STIMULUS
317	MASTURBATION
317	OF FREE
317	CIRCADIAN
317	FREE TESTOSTERONE
317	DROP
317	FREE
317	DAY
317	0.05
317	VISUAL STIMULUS
318	RATIOS
318	STATISTICAL
318	TESTOSTERONE, FREE
318	TESTOSTERONE
318	CORTISOL
318	FREE TESTOSTERONE
318	TOTAL TESTOSTERONE
318	TOTAL
318	OBSERVED
318	CHANGE
318	FREE
319	CONCLUSIONS
320	RATIOS
320	CONCENTRATIONS
320	TESTOSTERONE
320	MASTURBATION
320	MAY HAVE
320	EFFECT
320	BUT
320	ASSUMED
320	FREE TESTOSTERONE
320	HORMONAL
320	POTENTIAL
320	HAVE
320	FREE
321	SARCOPENIA
321	MUSCLE MASS
321	FRAILTY
321	FUNCTION
321	RELATED
321	SKELETAL MUSCLE MASS
321	LOSS
321	MARKER
321	IDENTIFIED
321	AGE
321	SKELETAL MUSCLE
321	MUSCLE
321	LOSS OF
321	SKELETAL
321	MASS
322	SARCOPENIA
322	AORTIC VALVE
322	TAVI
322	EVENTS
322	AORTIC
322	TRANSCATHETER
322	EXAMINED
322	FOLLOWING
322	TRANSCATHETER AORTIC VALVE IMPLANTATION
322	VALVE
322	IMPLANTATION
322	ADVERSE EVENTS
322	ADVERSE
322	ASSOCIATION
323	COHORT STUDY
323	STUDY
323	TORONTO GENERAL HOSPITAL
323	RETROSPECTIVE
323	RETROSPECTIVE COHORT STUDY
323	GENERAL HOSPITAL
323	GENERAL
323	HOSPITAL
323	TORONTO
323	COHORT
324	PREOPERATIVE
324	TAVI
324	COMPUTED
324	TIME PERIOD
324	TOMOGRAPHY
324	PERIOD
324	2007
324	COMPUTED TOMOGRAPHY
324	INCLUDED
324	TIME
324	2017
324	PATIENTS
325	VERTEBRAL LEVEL
325	PSOAS MUSCLE
325	VERTEBRAL
325	AREA
325	USING
325	SMI
325	LEVEL
325	CALCULATED
325	SKELETAL MUSCLE
325	MUSCLE
325	HEIGHT
325	SKELETAL
325	DIVIDED
325	INDEX
326	SARCOPENIA
326	LOWEST
326	VARIOUS
326	MEAN
326	MEDIAN
326	SMI
326	SPECIFIC
326	QUARTILE
326	CALCULATED
326	MEASURES
326	SEX-SPECIFIC
326	SEX
326	INCLUDING
327	MORBIDITY
327	PRIMARY
327	COMPOSITE
327	HOSPITAL MORTALITY
327	GASTROINTESTINAL COMPLICATIONS
327	DEFINED
327	HOSPITAL
327	ADVERSE EVENTS
327	CARDIOVASCULAR
327	OUTCOME
327	MORTALITY
327	ADVERSE
327	GASTROINTESTINAL
327	NEUROLOGIC
327	PRIMARY OUTCOME
327	INCLUDING
327	ACCESS
327	POSTOPERATIVE
327	PULMONARY
327	IN-HOSPITAL MORTALITY
327	EVENTS
327	RELATED
327	COMPLICATIONS
328	SARCOPENIA
328	MULTIVARIATE LOGISTIC REGRESSION
328	DETERMINE
328	EVENTS
328	PERFORMED
328	REGRESSION
328	ADVERSE
328	LOGISTIC
328	ADVERSE EVENTS
328	LOGISTIC REGRESSION
328	ASSOCIATION
329	YEARS
329	MEAN
329	AGE
329	INCLUDED
329	TOTAL
329	PATIENTS
330	BURDEN
330	FAILURE
330	CONGESTIVE
330	HEART
330	CONGESTIVE HEART FAILURE
330	BASELINE
330	HEART FAILURE
330	COMORBIDITY
330	HIGH
331	OCCURRED
331	POSTOPERATIVE
331	EVENTS
331	PATIENTS
331	ADVERSE EVENTS
331	ADVERSE
332	1.33
332	SEX-SPECIFIC
332	SEX
332	ADVERSE EVENTS
332	2.16
332	ODDS
332	CORRELATED
332	1.24
332	DEMONSTRATED
332	ADVERSE
332	CONFIDENCE
332	LOWEST
332	LESS THAN
332	QUARTILE
332	REGRESSION
332	LOGISTIC REGRESSION
332	POSTOPERATIVE
332	RATIO
332	EVENTS
332	MEAN
332	SMI
332	SPECIFIC
332	LOGISTIC
332	ODDS RATIO
333	ANALYSIS
333	LOWEST
333	EVENTS
333	ADVERSE EVENTS
333	QUARTILE
333	SMI
333	SPECIFIC
333	PREDICTOR
333	MULTIVARIATE ANALYSIS
333	SEX
333	SEX-SPECIFIC
333	INDEPENDENT
333	ADVERSE
334	SARCOPENIA
334	PSOAS MUSCLE
334	MORBIDITY
334	TAVI
334	IN-HOSPITAL MORTALITY
334	RADIOLOGIC
334	ASSOCIATED
334	MORTALITY
334	HOSPITAL MORTALITY
334	MUSCLE
334	DEFINED
334	ASSOCIATED WITH
334	MEASUREMENTS
334	HOSPITAL
334	FOLLOWING
336	OBJECTIVES
337	EXPERIENCE
337	PUBLIC HEALTH
337	CHALLENGES
337	ABILITY
337	INFLUENCE
337	PEOPLE
337	COVID-19
337	SIGNIFICANT
337	FOLLOW
337	HEALTH
337	FIRST NATIONS
337	ABILITY TO
337	PUBLIC
337	RESERVE
338	STUDY
338	ADVICE
338	PUBLIC HEALTH
338	EXPERIENCES
338	RELATED
338	PERCEPTIONS
338	COVID-19
338	HEALTH ADVICE
338	TO DESCRIBE
338	ALBERTA
338	HEALTH
338	FIRST NATIONS
338	COMMUNITY
338	DESCRIBE
338	PUBLIC
339	ADVICE
339	PUBLIC HEALTH
339	CHALLENGES
339	HEALTH
339	FOLLOWING
339	PUBLIC
340	METHODS
341	SURVEY
341	ONLINE
341	LEADERSHIP
341	DEPLOYED
341	CROSS
341	APRIL
341	FIRST NATIONS
341	CROSS-SECTIONAL
341	SECTIONAL
341	JUNE
341	STAFF
341	2020
341	CROSS-SECTIONAL SURVEY
342	ADVICE
342	PUBLIC HEALTH
342	CURB
342	ADVICE TO
342	ASSESSED
342	COVID-19
342	HEALTH
342	LARGE
342	FIRST NATIONS
342	APPROPRIATENESS
342	COMMUNITY
342	HEALTH ADVICE
342	PUBLIC
343	QUALITATIVE
343	QUANTITATIVE
343	DATA
343	DESCRIBED
343	QUALITATIVE DATA
344	RESULTS
345	ADULTS
345	106
345	TOTAL
345	FEMALE
345	80%
345	LIVING
345	RESERVE
346	ACCESSING
346	DIFFICULTY
346	SIGNIFICANT
346	EMPLOYMENT
346	STATUS
346	EMPLOYMENT STATUS
346	FOOD
347	MEDICAL CARE
347	ESSENTIAL
347	ACCESSING
347	DIFFICULT
347	PEOPLE
347	CLOTHING
347	FOUND
347	INCOME
347	CARE
347	TRANSPORTATION
347	FOOD
347	MEDICAL
347	LOWER
348	DIFFICULTIES
348	SUPPLIES
348	ESSENTIAL
348	EXPERIENCES
348	LOST
348	ACCESSING
348	ASSOCIATED
348	COVID-19
348	DESCRIBED
348	INCOME
348	ASSOCIATED WITH
348	RESPONDENTS
349	DIFFICULT
349	PROPER
349	EASY
349	FOUND
349	DISTANCE
349	RESPONDENTS
349	HANDWASHING
350	PUBLIC HEALTH
350	PERSONAL
350	DOMAIN
350	EXPERIENCED
350	UNABLE TO
350	RESPONDENTS
350	DIFFICULTIES
350	TO CONTROL
350	CONTROL
350	FOLLOWING
350	PUBLIC
350	FAMILY
350	UNABLE
350	SOCIAL
350	ADVICE
350	EASY
350	BUT
350	FOUND
350	HEALTH
350	ACTIONS
350	SAFETY
350	HEALTH ADVICE
351	CLEAR
351	WANTING
351	PEOPLE
351	CRITICAL
351	BUT
351	COVID-19
351	STATED
351	INFORMATION
351	RESPONSE
352	CONCLUSION
353	IMPACT
353	ELECTRONIC
353	OUTCOMES
353	BASED
353	CESSATION
353	NICOTINE
353	CANADA
353	SMOKING
353	COSTS
353	DELIVERY
353	DETERMINED
353	ENDS
353	SMOKING CESSATION
353	DELIVERY SYSTEMS
353	RATES
353	EFFECT
353	INITIATION
353	SYSTEMS
353	SMOKING INITIATION
353	HEALTH OUTCOMES
353	HEALTH
353	ELECTRONIC NICOTINE DELIVERY SYSTEMS
354	YEARS
354	QUALITY-ADJUSTED LIFE YEARS
354	UNAVAILABLE
354	MODELS
354	AGED
354	QUALITY
354	HEALTH CARE
354	QUO
354	CESSATION
354	ADJUSTED
354	USED
354	COMPLETELY
354	HEALTH CARE COSTS
354	LIFE YEARS, QUALITY-ADJUSTED
354	MARKOV MODELS
354	CARE
354	STATUS
354	HEALTH CARE PROVIDER
354	SMOKING
354	ESTIMATE
354	COSTS
354	COHORTS
354	GENDER-SPECIFIC
354	PRESCRIPTION
354	ADDITION
354	ENDS
354	SMOKING CESSATION
354	TOOLS
354	LIFETIME
354	SCENARIOS
354	LIFE
354	ADJUSTED LIFE YEARS
354	CARE PROVIDER
354	AVAILABLE
354	MALES
354	GENDER
354	CURRENTLY
354	RELATED
354	PROVIDER
354	SPECIFIC
354	HEALTH
354	FEMALES
355	ANALYSIS
355	HEALTH CARE SYSTEM
355	PERSPECTIVE
355	SYSTEM
355	HEALTH
355	CARE
355	FUNDED
355	HEALTH CARE
356	OBTAINED
356	VALUES
356	MONTE
356	CARLO
356	MONTE CARLO
356	EXPECTED
356	BASED
356	OUTCOMES
356	INDIVIDUALS
356	MONTE CARLO SIMULATION
356	SIMULATION
356	EXPRESSED
356	1000
357	YEARS
357	CAD
357	UNAVAILABLE
357	871
357	960
357	AGED
357	553
357	568
357	HEALTH CARE
357	HEALTH CARE COSTS
357	CARE
357	SMOKING
357	COSTS
357	570
357	PRESCRIPTION
357	ENDS
357	QALYS
357	LIFE
357	AVAILABLE
357	MALES
357	645
357	897
357	RELATED
357	HEALTH
357	894
358	YEARS
358	CAD
358	UNAVAILABLE
358	610
358	HEALTH CARE
358	438
358	076
358	HEALTH CARE COSTS
358	CARE
358	SMOKING
358	856
358	COSTS
358	PRESCRIPTION
358	ENDS
358	QALYS
358	242
358	LIFE
358	AVAILABLE
358	926
358	RELATED
358	HEALTH
358	FEMALES
359	ENDS
359	AVAILABLE
359	UNAVAILABLE
359	DOMINANT
359	STATUS
359	QUO
359	PRESCRIPTION
360	UNAVAILABLE
360	CANADIAN
360	POPULATION
360	LIKELY
360	THESE
360	HEALTH CARE
360	HEALTH CARE COSTS
360	CARE
360	POLICY
360	COSTS
360	PRESCRIPTION
360	ENDS
360	REDUCE
360	POPULATION HEALTH
360	AVAILABLE
360	RESULTS
360	HEALTH
360	INCREASE
360	CHANGE
361	BACKGROUND
362	PUBLIC
362	PUBLIC HEALTH
362	MEDICINES
362	PHARMACEUTICAL
362	WEAK
362	POSE
362	REGULATORY
362	BUT
362	MECHANISMS
362	THREAT
362	HEALTH
362	FALSIFIED MEDICINES
362	WORLD
362	SUBSTANDARD
363	MEDICINES
363	EVENT
363	PRESCRIPTION OF
363	PATIENT
363	CONSUMER
363	MEDICAL PRACTITIONER
363	MAKER
363	PRACTITIONER
363	DECISION
363	DECISION MAKER
363	MEDICAL
363	IS A
363	PRESCRIPTION
364	AIM
365	IDENTIFICATION
365	COUNTERFEIT MEDICINE
365	PREVENTIVE
365	TECHNOLOGIES
365	DRIVERS
365	OF-
365	COUNTERFEIT
365	MEDICINES
365	MEDICINE
365	CARE
365	OVERT
365	STUDY
365	MPS
365	ABIA STATE
365	MEASURES
365	DESCRIBING
365	AWARENESS
365	SUBSTANDARD
365	POINT
365	STATE
365	ABIA
366	METHODS
367	STUDY
367	CROSS-SECTIONAL STUDY
367	WAS A
367	CROSS
367	MPS
367	ABIA STATE
367	CROSS-SECTIONAL
367	SECTIONAL
367	178
367	NIGERIA
367	STATE
367	ABIA
368	IDENTIFICATION
368	SELF-ADMINISTERED
368	DATA
368	USING
368	AWARENESS
368	OVERT
368	ADMINISTERED
368	SELF
368	QUESTIONNAIRE
368	INFORMATION
368	SELF-ADMINISTERED QUESTIONNAIRE
368	ITS
368	COLLECTED
368	ELICITED
369	PREVENTIVE
369	MEDICINES
369	MEASURES
369	DRIVERS
369	FALSIFIED MEDICINES
369	SUBSTANDARD
370	RESULTS
371	RANGE
371	YEARS
371	MEAN
371	AGE
371	RESPONDENTS
372	MALES
373	MOBILE
373	POINT-OF-CARE
373	GRAPHICS
373	LABELLING
373	NUMBERS
373	RESPONDENTS
373	MAN
373	AWARE
373	OF-
373	IDENTIFIED
373	CARE
373	OVERT
373	100
373	AUTHENTICATION
373	PACKAGING
373	100%
373	PRINTING
373	BEING
373	TYPES
373	POINT
374	PRINTING
374	100
374	TECHNOLOGIES
374	PACKAGING
374	LABELLING
374	100%
375	CONSTRAINT
375	PREDOMINANT
375	100
375	BARRIER
375	OVERT
375	TIME
375	100%
375	PREDISPOSING
376	ANALGESICS
376	MEDICINES
376	SUBSTANDARD MEDICINES
376	ANTI-MALARIAL
376	100
376	BACTERIAL
376	100%
376	ANTI-BACTERIAL
376	SUBSTANDARD
376	CLASSES
377	FAILURES
377	PHARMACEUTICAL PRODUCTS
377	MEDICINES
377	POOR
377	PHARMACEUTICAL
377	DANGER
377	REGULATORY
377	SYSTEMS
377	100%
377	100
377	REGULATORY SYSTEMS
377	TREATMENT
377	TREATMENT FAILURES
377	FALSIFIED MEDICINES
377	COMMON
377	DRIVER
377	RESPONDENTS
377	SUBSTANDARD
378	SECURING
378	PREVENTIVE
378	MEDICINES
378	CHAIN
378	100
378	MEASURE
378	RECOMMENDED
378	SUPPLY
378	100%
379	CONCLUSION
380	OF-
380	TO TRANSLATE
380	TRANSLATE
380	BUT
380	POINT-OF-CARE
380	CARE
380	OVERT
380	VERY HIGH
380	TYPES
380	AWARENESS
380	POINT
380	APPEAR
380	HIGH
380	DID
381	PRINTING
381	OVERT
381	TECHNOLOGIES
381	PACKAGING
381	LABELLING
382	CONSTRAINT
382	PREDOMINANT
382	IDENTIFIED
382	BARRIER
382	OVERT
382	TIME
382	POSSIBLE
383	MEDICINES
383	ANTI-MALARIAL
383	ANALGESIC
383	BACTERIAL
383	FALSIFIED MEDICINES
383	ANTI-BACTERIAL
383	SUBSTANDARD
383	CLASSES
384	RESULT
384	FAILURES
384	PHARMACEUTICAL PRODUCTS
384	MEDICINES
384	POOR
384	PHARMACEUTICAL
384	REGULATORY
384	REGULATORY SYSTEM
384	SYSTEM
384	TREATMENT
384	THESE
384	TREATMENT FAILURES
384	FALSIFIED MEDICINES
384	DRIVER
384	SUBSTANDARD
385	SECURING
385	SUPPLY
385	PREVENTIVE
385	SERVE
385	MEDICINAL PRODUCTS
385	MEASURE
385	CHAIN
385	EFFECTIVE
386	KEYWORDS
387	COUNTERFEIT MEDICINE
387	COUNTERFEIT
387	IDENTIFICATION
387	MEDICINE
387	NIGERIA
387	TECHNOLOGIES
388	PROVIDE
388	INFANT
388	ORGANIZATIONS
388	PRENATAL
388	INFANT HEALTH
388	PRENATAL NUTRITION
388	WOMEN
388	TO PROVIDE
388	CANADA
388	NUTRITION
388	HEALTH SERVICES
388	VULNERABLE
388	MATERNAL
388	INFANT HEALTH SERVICES
388	ECONOMICALLY
388	SERVICES
388	HEALTH
388	CPNP
388	PROGRAM
388	COMMUNITY
389	PROVIDE
389	RESEARCH PROGRAM
389	BREASTFEEDING SUPPORT
389	SUPPORT
389	RESEARCH
389	EXPLORING
389	PARTICIPATION
389	INVESTIGATED
389	CHARACTERISTICS
389	PART OF
389	TO PROVIDE
389	TORONTO
389	PSYCHOSOCIAL
389	OUR
389	SOCIODEMOGRAPHIC
389	BREASTFEEDING
389	ENROLLED
389	CLIENTS
389	ASSOCIATIONS
389	POSTNATAL
389	CPNP
389	PROGRAM
389	SITE
390	2016
390	2013
390	SOUTHWEST
390	WOMEN
390	SITE
390	DATA
390	REGISTERED
390	CPNP
390	TORONTO
390	CHARTS
390	COLLECTED
391	TIMES
391	WEEKS
391	NUMBER OF
391	PROGRAM PARTICIPATION
391	PRENATAL
391	DIMENSIONS
391	RECEIVED
391	DURATION
391	PARTICIPATION
391	CHARACTERISTICS
391	USED
391	VISITS
391	REGRESSION ANALYSES
391	GESTATIONAL AGE
391	PRENATAL PROGRAM
391	MATERNAL
391	REGRESSION
391	ASSOCIATIONS
391	NUMBER
391	INTENSITY
391	GESTATIONAL
391	NUMBER OF TIMES
391	AGE
391	PROGRAM
391	INITIATION
391	ASSESS
392	YEARS
392	5.7
392	OUTSIDE
392	HOUSEHOLD
392	ADJUSTED
392	CUT
392	FAMILY SIZE
392	CANADA
392	BORN
392	SIZE
392	STATISTICS
392	FAMILY
392	SINGLE
392	INCOME
392	CLIENTS
392	MEAN
392	INCOMES
392	AGE
392	LOW
392	80%
393	CHARACTERISTIC
393	ASSOCIATED
393	INCOME
393	ASSOCIATED WITH
393	DIMENSIONS
393	PARTICIPATION
394	TIMES
394	0.16
394	NUMBER
394	CUT
394	WEEKS
394	EARLIER
394	COMPARED
394	NUMBER OF
394	INCOME
394	LOW
394	ENROLLED
394	HIGHER
394	PROGRAM
394	CLIENTS
394	VISITS
394	LIVING
395	CHARACTERISTICS
395	WOMEN
395	OUR
395	MATERNAL
395	BASED
395	CPNP
395	SITE
395	FINDINGS
395	VULNERABLE
395	PARTICIPATION
396	SERVICE
396	EVIDENCE
396	MONITORING
396	DECISIONS
396	PROGRAM
396	SITE
396	GUIDE
397	PERINATAL
397	SERVICES
397	WOMEN
397	NEW
397	MODELS
397	PROGRAM
397	RESEARCH
397	NEEDED
397	DELIVERY
397	VULNERABLE
397	ENHANCE
398	RHINOPLASTY
398	CHALLENGE
398	CONSISTENT
398	ACT
398	RESULTS
398	OUTSTANDING
398	COMMON
398	PROCEDURES
398	COMMON PROCEDURES
398	ONE OF
399	RHINOPLASTY
399	CONDITIONS
399	TECHNIQUE
399	REDUCTION
399	PRESCRIBED
399	ALAR
399	BASE
399	IS A
400	PURPOSE
400	CLOSURE
400	GOOD
400	WOUND
400	REQUIRES
400	USING
400	SUTURES
400	RESULTS
400	SCAR
400	TYPES
400	NECESSARY
400	WOUND CLOSURE
400	SATISFACTION
400	PATIENTS
401	SUTURING
401	MATERIAL
401	RESECTION
401	SURGICAL
401	RESULTS
401	SURGICAL RESECTION
401	USING
401	SCAR
401	ALAR
401	TYPES
401	DIFFERENT
401	BASE
401	EVALUATE
402	COHORT STUDY
402	STUDY
402	SAUDI ARABIA
402	KINGDOM
402	KINGDOM OF SAUDI ARABIA
402	RIYADH
402	RETROSPECTIVE COHORT STUDY
402	RETROSPECTIVE
402	SAUDI
402	ARABIA
402	KING
402	UNIVERSITY HOSPITAL
402	HOSPITAL
402	COHORT
402	IS A
402	UNIVERSITY
403	STUDY
403	FOR PATIENT
403	PATIENT
403	RESECTION
403	PERFORMED
403	PERFORMED BY
403	PERFORMING
403	POST-OPERATIVE
403	REVIEWING
403	PHOTOGRAPHY
403	ALAR
403	RECORDS
403	POST
403	BASE
403	OPERATIVE
404	POLYPROPYLENE
404	OTHER GROUP
404	GROUP
404	WOUND
404	SUTURES
404	INTERRUPTED
404	ALAR
404	CLOSED
404	GROUPS
404	BASE
404	PATIENTS
404	GROUP OF PATIENTS
404	DIVIDED
405	VISUAL
405	USED
405	VIEWS
405	BASAL
405	TO INVESTIGATE
405	VISUAL ANALOG SCALE
405	SCALE
405	ANALOG
405	INVESTIGATE
406	POLYPROPYLENE
406	STUDY
406	MALES
406	GROUP
406	INCLUDED
406	FEMALES
406	SECOND
406	GROUPS
406	PATIENTS
406	DIVIDED
407	REPORTED BY
407	GROUP
407	SIGNIFICANT
407	DIFFERENCE
407	SCAR
407	82.5
407	SECOND
407	GROUPS
407	REPORTED
408	POLYPROPYLENE
408	RESULT
408	WOUND
408	SUTURES
408	SURGICALLY
408	CLOSING
408	ALAR
408	POST
408	BASE
409	MULTIDISCIPLINARY
409	FRACTURED
409	SPRING
409	SOURCE
409	IS DERIVED FROM
409	VARIATION
409	TEMPORAL VARIATION
409	THERMAL SPRING
409	MODEL OF
409	CONCEPTUAL MODEL
409	CIRCULATION
409	CONCEPTUAL
409	MODEL
409	SETTING
409	PATHWAYS
409	APPROACH
409	THERMAL
409	LIMESTONE
409	LOW
409	ENTHALPY
409	DERIVED
409	TEMPORAL
410	EAST
410	IRELAND
410	PROFILE
410	THERMAL
410	VARIABLE
410	THERMAL SPRING
410	TEMPERATURE PROFILE
410	TEMPERATURE
410	SPRING
410	CENTRAL
410	COMPLEX
410	MAXIMUM
410	IS A
411	ANALYSIS
411	INVESTIGATE
411	THREE-DIMENSIONAL
411	AMT
411	SURVEY
411	WITH TIME
411	OPERATION
411	PREVIOUSLY
411	PUBLISHED
411	DATA
411	SYSTEM
411	INFORMATION
411	TIME
411	AUDIO
411	TO INVESTIGATE
411	COMBINED
412	ANALYSIS
412	TIMES
412	THERMAL
412	BASIN
412	VARIABILITY
412	DUBLIN
412	FRACTURED
412	BUT
412	CARBONIFEROUS
412	DISCHARGE
412	DISPLAY
412	TEMPERATURE
412	MEASUREMENTS
412	WATERS
412	TIME
412	SUGGEST
412	FLOW
413	ELECTRICAL RESISTIVITY
413	PROMINENT
413	FAULT
413	MODEL
413	LIMESTONE
413	REVEALED
413	ALIGNED 
413	ALIGNED
413	MODEL OF
413	CONTACT
413	PROBABLE
413	AGE
413	SUBSURFACE
413	ENHANCED
413	STRUCTURES
413	RESISTIVITY
413	ELECTRICAL
413	CENOZOIC
414	BASIN
414	ALLOWED
414	LIKELY
414	DUBLIN
414	THESE
414	DEPTHS
414	ESTIMATED
414	SUCCESSION
414	DEEP
414	CONDUITS
414	CIRCULATION
414	FACILITATING
414	BEDROCK
414	OPERATION
414	LIMESTONE
414	CREATED
414	INTERSECTION
414	STRUCTURES
414	240
415	HYPOTHESIS
415	RESULT
415	MAXIMUM TEMPERATURE
415	SUPPORT
415	STUDY SUPPORT
415	DISCHARGE
415	HEATING
415	CIRCULATION
415	WATERS
415	CIRCULATION SYSTEM
415	STUDY
415	TEMPERATURE
415	OBSERVED
415	CONTROLLED
415	RAPID
415	WINTER
415	RECIRCULATION
415	RESULTS
415	SYSTEM
415	SIMULTANEOUS
415	INFILTRATION
415	INCREASED
415	MAXIMUM
417	BACKGROUND
418	UROGENITAL
418	INTESTINAL
418	CHRONIC DISEASE
418	FORMS
418	WORMS
418	SCHISTOSOMIASIS
418	MAIN
418	CAUSED BY
418	PARASITIC WORMS
418	PARASITIC
418	CHRONIC
418	ACUTE
418	DISEASE
419	REPRODUCTIVE
419	GIRLS
419	CERVICAL
419	FREQUENTLY
419	SEVERE
419	FORM
419	WOMEN
419	GENITAL
419	SCHISTOSOMIASIS
419	LEFT
419	FGS
419	INFECTIONS
419	CANCER
419	FEMALE GENITAL
419	UROGENITAL
419	RESULTING
419	SEXUALLY
419	CONFUSED
419	STIS
419	HEALTH
419	COMPLICATIONS
419	RESULTING IN
419	UNTREATED
419	REPRODUCTIVE HEALTH
419	TRANSMITTED
419	CERVICAL CANCER
419	FEMALE
419	LEAD
420	REPRODUCTIVE
420	COMMUNITIES
420	PROFESSIONALS
420	WOMEN
420	IMPACT
420	AWARENESS
420	HEALTH
420	HEALTH PROFESSIONALS
420	LOW
420	REPRODUCTIVE HEALTH
420	ITS
420	POORLY
420	REMAINS
420	TRAINING
420	MEDICAL
420	FGS
420	AFFECTED
421	REPRODUCTIVE
421	SUB
421	INFECT
421	SEXUAL
421	2019
421	134
421	NEGLECTED
421	HIV/AIDS
421	HIV
421	AFRICA
421	TROP
421	DESCRIBED
421	ONE OF
421	SUB-SAHARAN AFRICA
421	PROGRAMME
421	FGS
421	JOINT
421	SUB-
421	DIS
421	AIDS
421	2006
421	HEALTH
421	REPRODUCTIVE HEALTH
421	UNAIDS
421	UNITED NATIONS
421	BMC
422	REPRODUCTIVE
422	BURDEN
422	NEGLECT
422	WOMEN
422	TROPICAL
422	PREVENTABLE
422	HEALTH
422	TROPICAL DISEASE
422	REPRODUCTIVE HEALTH
422	DECREASE
422	END
422	AWARENESS
422	REQUIRED
422	INCREASED
422	FGS
422	KNOWLEDGE
422	DISEASE
423	METHODS
424	PUBLIC HEALTH
424	VIRTUAL
424	TREATMENT
424	WORLD HEALTH ORGANIZATION
424	HEALTH SYSTEM
424	WORLD
424	DIAGNOSIS
424	ESTABLISH
424	HEALTH ORGANIZATION
424	COLLABORATION
424	SKILLS
424	MEDICAL
424	FGS
424	PUBLIC
424	WORLD HEALTH ORGANIZATION (WHO)
424	COMPETENCIES
424	LEVELS
424	PREVENTION
424	WORKSHOPS
424	INTERACTIVE
424	PARTICIPANTS
424	WORLD HEALTH
424	ORGANIZATION
424	SYSTEM
424	HEALTH
424	ENGAGING
425	REVIEWED
425	PARTICIPANTS
425	COMPETENCIES
425	GROUPS, PEER
425	SMALL GROUPS
425	SMALL
425	FINALIZED
425	GROUPS
425	PEER
425	PEER-REVIEWED
426	RESULTS
427	PROCESS
427	IDENTIFICATION
427	CLINICAL SETTING
427	WORKING
427	SETTING
427	MANAGEMENT
427	CATEGORIES
427	FGS
427	OF HEALTH
427	CLINICAL
427	DIAGNOSIS
427	PREVENTION
427	HEALTH
427	WORKERS
427	COMMUNITY
427	NEEDED
427	SKILLS
427	LED
428	PELVIC EXAM
428	EXAM
428	DO NOT
428	FGS
428	RELATE
428	DIAGNOSIS
428	SEVEN
428	PELVIC
428	INCLUDING
429	CLINICAL SETTING
429	SETTING
429	CLINICAL
429	TREAT
429	APPROPRIATE
429	BEHAVIORS
429	REQUIRED
429	FGS
430	IDENTIFICATION
430	RISK
430	SETTING
430	WOMEN
430	ADDRESS
430	PREVENTION
430	COMMUNITY
430	AT RISK
431	CONCLUSION
432	SUB
432	GIRLS
432	PREPARE
432	TREATMENT
432	DEFINING
432	DIAGNOSIS
432	CRITICAL STEP
432	AFRICA
432	MANAGEMENT
432	WOMEN
432	NECESSARY
432	TRAINED
432	TO PREPARE
432	SUB-SAHARAN AFRICA
432	SKILLS
432	FGS
432	PROFESSIONALS
432	PROPER
432	CRITICAL
432	STEP
432	SUB-
432	HEALTH
432	HEALTH PROFESSIONALS
432	IS A
433	OBTAINED
433	DEGREE
433	MEDICINE
433	DOCTORAL DEGREE
433	FACULTY
433	PARIS
433	THIRTEEN
434	AMERICA
434	CANADIAN
434	TURN
434	CENTURY
434	MAJOR
434	BACTERIOLOGY
434	DEVELOPMENT
434	FORMATION
434	CANADA
434	TRENDS
434	RISE
434	FRANCE
434	PROFESSIONAL
434	FRENCH
434	SUP
434	PLAYED
434	ROLE
434	BOURGEOISIE
434	HISTORY
434	STUDIES
434	FRENCH-CANADIAN
434	NATIONALISM
435	SANT
435	AVAILABLE
435	QUE
435	USING
435	CAREERS
435	PIERRE
435	PARIS
435	THESE
435	UNPUBLISHED
435	SOURCES
435	STUDENT
435	THESES
435	SANTÉ
435	DATABASE
435	MEDICAL
435	MEDICAL DOCTORS
435	ARTICLE
436	MEDICAL
436	CANADIAN
436	TRAVELS
436	IMPACT
436	MEDICAL PROFESSION
436	PROFESSION
436	COLONY
436	EXAMINING
436	AMERICAN
436	THESE
436	ITS
436	IMPERIAL
436	PARIS
436	RELATIONSHIP
436	CAPITAL
436	NORTH
436	DOCTORS
436	NORTH AMERICAN
437	STUDY
437	SAUDI ARABIA
437	CROSS-SECTIONAL STUDY
437	ACROSS
437	CROSS
437	2015
437	2019
437	DISTRIBUTION
437	ARABIA
437	CROSS-SECTIONAL
437	SECTIONAL
437	BEDS
437	SAUDI
437	HOSPITAL
438	ADEQUATE
438	SYSTEMS
438	BASIC
438	ACCESS TO HEALTH CARE
438	HUMAN
438	HEALTH CARE SYSTEMS
438	HEALTH
438	CARE
438	RIGHT
438	HEALTH CARE
438	CONSIDERED
438	HUMAN RIGHT
438	ACCESS
439	EFFICIENT
439	SERVICES
439	IMPORTANT
439	NEED
439	POSSIBLE
439	HEALTH
439	CARE
439	HEALTH CARE
439	DELIVERED
439	HEALTH CARE SERVICES
440	SAUDI ARABIA
440	RESOURCE
440	EVALUATED
440	ACROSS
440	RESOURCE ALLOCATION
440	2015
440	2019
440	DISTRIBUTION
440	ARABIA
440	ASSESS
440	ALLOCATION
440	BEDS
440	INEQUALITIES
440	SAUDI
440	HOSPITAL
440	IN HOSPITAL
441	STUDY
441	CROSS-SECTIONAL STUDY
441	STATISTICAL
441	CROSS
441	PUBLISHED
441	DATA
441	OF HEALTH
441	PERIOD
441	2015
441	HEALTH
441	2019
441	CROSS-SECTIONAL
441	SECTIONAL
442	NUMBER
442	POPULATION
442	REGIONS
442	NUMBER OF
442	100
442	CALCULATED
442	HEALTH
442	BEDS
442	HOSPITAL
443	GENERATION
443	GINI
443	CURVE
443	PERFORMED
443	DISTRIBUTION
443	PARAMETERS
443	BEDS
443	ASSESS
443	INDEX
444	CORRELATION
444	POPULATION
444	PEARSON
444	COEFFICIENT
444	CALCULATED
444	HEALTH
444	REGION
444	BEDS
444	ASSESS
445	POPULATION
445	RATIO
445	IMPROVED
445	2015
445	2019
445	AREAS
445	32.5
445	BEDS
445	INCREASED
445	HOSPITAL
446	PUBLIC SECTOR
446	0.21
446	SECTOR
446	PRIVATE
446	MEAN
446	GINI
446	PRIVATE SECTOR
446	CALCULATED
446	DISTRIBUTION
446	BED
446	PUBLIC
446	INDEX
447	WAS A
447	CORRELATION
447	POPULATION
447	REGIONS
447	RIYADH
447	EASTERN
447	BEDS
447	POSITIVE
447	STRONG
447	HOSPITAL
447	STRONG POSITIVE
448	HOSPITAL BED
448	DISTRIBUTIONS
448	SAUDI ARABIA
448	SECTOR
448	PRIVATE
448	PRIVATE SECTOR
448	ARABIA
448	LIE
448	BED
448	OBSERVED
448	INEQUALITIES
448	SAUDI
448	HOSPITAL
448	IN HOSPITAL
449	AWARE
449	WORK
449	VISION
449	2030
449	RECOMMENDED
449	GOALS
449	INEQUALITIES
449	SAUDI
449	POSSIBLE
451	OBJECTIVES
452	PUBLIC HEALTH
452	BODY WEIGHT
452	BEHAVIOURS
452	ARRAY
452	FOCUSED
452	OBESITY
452	PHYSICAL
452	BODY
452	STATUS
452	OBESITY PREVENTION
452	DIVERSITY
452	PUBLIC
452	ADOLESCENT
452	PREVENTION
452	SOCIAL
452	IDENTITIES
452	INTERVENTIONS
452	MAY BE
452	PHYSICAL ACTIVITY
452	SOCIAL FACTORS
452	DIET
452	STIGMA
452	WEIGHT
452	ACTIVITY
452	HEALTH
452	EXPENSE
452	DISCRIMINATION
452	HAVE
453	EXTENT
453	VERSUS
453	WEIGHT
453	NEEDED
453	CONTRIBUTE 
453	ADOLESCENTS
453	BEHAVIOURS
453	HEALTH
453	CONTRIBUTE
453	SOCIAL
453	STATUS
453	TO EXAMINE
453	RESEARCH
453	SOCIAL FACTORS
454	STUDY
454	WEIGHT
454	OBJECTIVE
454	BEHAVIOURS
454	SOCIAL FACTORS
454	RELATIVE
454	CONTRIBUTION
454	HEALTH
454	SOCIAL
454	INDICES
454	STATUS
454	AIM
454	VERSUS
454	TO INVESTIGATE
454	INVESTIGATE
455	METHODS
456	PUBLIC
456	SURVEY DATA
456	YEARS
456	PUBLIC HEALTH
456	SURVEY
456	STUDENTS
456	CROSS
456	PART OF
456	DATA
456	PUBLIC HEALTH STUDENT
456	AGE
456	HEALTH
456	SECTIONAL
456	CROSS-SECTIONAL
456	STUDENT
456	TORONTO
456	COLLECTED
456	CROSS-SECTIONAL SURVEY
457	DEMOGRAPHIC
457	OBJECTIVE
457	SEXUAL
457	ORIENTATION
457	BEHAVIOURS
457	CONSUMPTION
457	PHYSICAL
457	STATUS
457	SEXUAL ORIENTATION
457	PERCEIVED
457	CONNECTEDNESS
457	MEASURES
457	SOCIAL
457	INCLUDED
457	PHYSICAL ACTIVITY
457	SCHOOL
457	DEMOGRAPHIC FACTORS
457	WEIGHT
457	ACTIVITY
457	GENDER
457	HEALTH
458	RESULTS
459	CONTRIBUTE 
459	SEXUAL
459	BEHAVIOURS
459	CONTRIBUTE
459	MODELS
459	CONSUMPTION
459	SEX
459	SUPPORTED
459	AMOUNTS
459	ECONOMIC
459	PARTIALLY
459	PHYSICAL
459	STATUS
459	REGRESSION MODELS
459	VARIABLE
459	MINORITY
459	COMPARED
459	REGRESSION
459	SOCIAL
459	SEXUAL MINORITY
459	PHYSICAL ACTIVITY
459	SOCIAL FACTORS
459	ACCESS
459	INDICES
459	WEIGHT
459	ACTIVITY
459	AGE
459	SIMILAR
459	VARIANCE
459	HEALTH
459	LATENT
459	FINDINGS
460	CONCLUSION
461	BASED
461	CONSUMPTION
461	TRADITIONAL
461	ACTIVE TRANSPORT
461	CONSIDERING
461	VEGETABLES
461	INDIVIDUAL
461	PHYSICAL
461	STATUS
461	ASSOCIATED WITH
461	ADOLESCENT
461	TRANSPORT
461	ACTIVE
461	SOCIAL
461	PHYSICAL ACTIVITY
461	SOCIAL FACTORS
461	SCHOOL
461	WEIGHT
461	ACTIVITY
461	MILK
461	VIEWS
461	FRUITS
461	ASSOCIATED
462	ACRS
462	FAILURE
462	ADHF
462	SYNDROME
462	DECOMPENSATED
462	HEART
462	ASSOCIATED
462	OUTCOMES
462	ASSOCIATED WITH
462	CARDIORENAL SYNDROME
462	ADVERSE OUTCOMES
462	PATIENTS
462	HEART FAILURE
462	DECOMPENSATED HEART FAILURE
462	ACUTE DECOMPENSATED HEART FAILURE
462	ADVERSE
462	ACUTE
463	BLOOD FLOW
463	ADHF
463	ASSESSED
463	USING
463	PROGNOSTIC
463	DOPPLER
463	ULTRASOUND
463	BLOOD
463	VENOUS
463	VENOUS BLOOD
463	SIGNIFICANCE
463	DOPPLER ULTRASOUND
463	FLOW
464	ACRS
464	POPULATION
464	IRD
464	SENSITIVE
464	RENAL
464	CONGESTION
464	SENSITIVE TO
464	DOPPLER
464	PARAMETERS
464	MAY BE
464	ADHF
464	DEMONSTRATED
464	RENAL CONGESTION
464	ASSOCIATION
465	ACUTE CORONARY SYNDROME
465	SYNDROME
465	HOSPITALIZED
465	ACS
465	ENROLLED
465	HOSPITALIZED PATIENTS
465	CORONARY
465	ADHF
465	PATIENTS
465	ACUTE
466	IRD
466	CARDIAC ULTRASOUND
466	CARDIAC
466	USING
466	ECHOCARDIOGRAPHY
466	TRANSDUCER
466	PATIENTS
466	ULTRASOUND
466	STANDARD
466	ULTRASOUND TRANSDUCER
466	INCLUDING
467	CYCLE
467	DURATION
467	CARDIAC CYCLE
467	STASIS
467	ABSENT
467	CARDIAC
467	RENAL
467	DIVIDED
467	VENOUS FLOW
467	TIME
467	DEFINED
467	VENOUS
467	FLOW TIME
467	VENOUS STASIS
467	FLOW
467	INDEX
468	AKI
468	KIDNEY DISEASE
468	CRITERIA
468	ACUTE KIDNEY INJURY
468	OUTCOME
468	GLOBAL
468	ASSESSED
468	INJURY
468	IMPROVING
468	PRIMARY
468	USING
468	OUTCOMES
468	KIDNEY
468	PRIMARY OUTCOME
468	KIDNEY INJURY
468	ACUTE
468	DISEASE
469	MIN
469	PRESSURE
469	3.2
469	CENTRAL VENOUS PRESSURE
469	MEASURED
469	L/MIN
469	PATIENTS
469	HIGHER
469	CARDIAC INDEX
469	ESTIMATED
469	CARDIAC
469	ECHOCARDIOGRAPHY
469	VENOUS
469	001
469	INDEX
469	SUP
469	VENOUS PRESSURE
469	USING
469	0.001
469	MM HG
469	COMPARED
469	ACS
469	CENTRAL VENOUS
469	2.1
469	2.0
469	BUT
469	4.6
469	SIMILAR
469	2.4
469	CENTRAL
469	ADHF
469	0.4
469	4 MM
469	0.6
470	IRD
470	0.0
470	0.001
470	ACS
470	001
470	NORMAL
470	ADHF
470	ABNORMAL
470	PATIENTS
471	PATIENTS
471	16.8
471	ΜMOL/L
471	RISE
471	001
471	OCCURRED
471	0.001
471	ACS
471	SERUM CREATININE
471	10.9
471	AKI
471	SERUM
471	ΜMOL
471	MEAN
471	STAGE
471	CREATININE
471	STAGE II
471	ADHF
471	III
472	AKI
472	CORRELATED
472	SEVERITY
472	ADHF
472	PATIENTS
472	004
473	AKI
473	DIAGNOSTIC BIOMARKER
473	ACRS
473	BIOMARKER
473	SETTING
473	ASSOCIATED
473	USEFUL
473	ASSOCIATED WITH
473	MAY BE A
473	MAY BE
473	ADHF
473	DIAGNOSTIC
473	PATIENTS
474	FINDING
474	IRD
474	SETTING
474	THERAPY
474	STUDIES
474	EFFICACY
474	NEEDED
474	POTENTIAL
474	EVALUATE
476	PURPOSE
477	OF PARENT
477	FOCUS
477	PREOPERATIVE
477	PRACTICE
477	TIMING
477	PREVENT
477	DIRECTED
477	ANXIETY
477	SHAPING
477	SPECIFIC
477	ANESTHETIC
477	EXPOSURE
477	MASK
477	TO PREVENT
477	EFFICACY
477	TO EXAMINE
477	CHILD
477	PARENT
478	METHODS
479	TRIAL
479	YEARS
479	RANDOMIZED
479	CONTROLLED TRIAL
479	CHILDREN
479	SURGERY DENTAL
479	PARENTS
479	110
479	DENTAL PROCEDURES
479	SEVEN
479	SURGERY
479	AGES
479	DAY SURGERY
479	INCLUDED
479	CONTROLLED
479	PROCEDURES
479	DENTAL
479	DAY
480	TIMES
480	FAMILIES
480	PRACTICE
480	ONE OF
480	MASK
480	GROUPS
480	SURGERY
480	WEEK
480	PARENT
480	ASSIGNED
480	PRIOR TO
480	DIRECTED
480	GROUP
480	SHAPING
480	GROUP 1
480	GROUP 2
480	INDUCTION
480	EXPOSURE
480	GROUP 3
480	PRIOR
480	DAY
481	MODIFIED
481	PREOPERATIVE
481	EXPERIENCE
481	COMPLIANCE
481	ANXIETY
481	USING
481	SURGERY
481	DAY SURGERY
481	CHILD
481	CHECKLIST
481	RATED
481	SCALE
481	INDUCTION
481	OBSERVER
481	DAY
482	RESULTS
483	ACROSS
483	ANXIETY
483	ANESTHETIC INDUCTION
483	SIGNIFICANT
483	RESULTS
483	ANESTHETIC
483	INDUCTION
483	CHILD
483	RATED
483	GROUPS
483	DEMONSTRATED
483	OBSERVER
484	SUB
484	0.06
484	0.04
484	GROUP
484	ANXIETY
484	SUP
484	EFFECT
484	GROUP 2
484	524
484	LOWER
484	MEDIUM
484	RATED
484	GROUP 3
484	DEMONSTRATED
484	OBSERVER
485	SUB
485	ANESTHESIA
485	0.06
485	INTERACTION
485	0.04
485	ANESTHESIA INDUCTION
485	SUP
485	SIGNIFICANT
485	ADMISSION
485	SMALL
485	THESE
485	MEDIUM
485	OBSERVED
485	TIME
485	GROUPS
485	INDUCTION
485	EFFECT
486	BEST
486	ANESTHESIA
486	COMPLIANCE
486	ANESTHESIA INDUCTION
486	GROUP
486	SCORES
486	GROUP 2
486	INDUCTION
486	0.04
486	GROUP 3
486	DEMONSTRATED
486	LOWER
487	CONCLUSION
488	PREOPERATIVE
488	COMPLIANCE
488	CONSIDERATION
488	TIMING
488	SETTING
488	ANXIETY
488	IMPORTANT
488	SURGERY
488	ADDRESS
488	DAY SURGERY
488	EXPOSURE
488	CHILD
488	MAY BE
488	MASK
488	DELIVERY
488	INDUCTION
488	DAY
489	PAEDIATRIC
489	NIGERIA
489	ENDOCRINOLOGY
489	IS A
490	ENDOCRINE DISORDERS
490	PAEDIATRIC
490	PRESENTATION
490	LATE
490	POOR
490	MISSED
490	REPORTS
490	MISSED DIAGNOSIS
490	DIAGNOSIS
490	PREVIOUS REPORTS
490	RESULTING IN
490	PREVIOUS
490	AWARENESS
490	DISORDERS
490	ENDOCRINE
490	SUGGEST
490	DEATH
490	RESULTING
491	PROVIDE
491	ESSENTIAL
491	EARLY
491	AIMS
491	REPORT
491	HOSPITAL
491	ENHANCE
491	PAEDIATRIC
491	PRESENTATION
491	MANAGEMENT
491	TO PROVIDE
491	ENDOCRINE DISORDERS
491	STUDY
491	INFORMATION
491	TEACHING HOSPITAL
491	DISORDERS
491	PREVALENCE
491	ENDOCRINE
491	TEACHING
492	MANAGED
492	STUDY
492	PAEDIATRIC
492	ENDOCRINE DISORDERS
492	RETROSPECTIVE STUDY
492	CHILDREN
492	YEAR
492	2020
492	2010
492	RETROSPECTIVE
492	MARCH
492	DISORDERS
492	ENDOCRINE
492	IS A
493	SPSS
493	EXTRACTED
493	DATA
493	ANALYZED
493	RECORDS
493	RELEVANT
493	ENTERED
493	PATIENTS
494	ENDOCRINE DISORDERS
494	STUDY
494	PAEDIATRIC
494	PERIOD
494	NEW
494	FORTY
494	0.42
494	520
494	CLINIC
494	DISORDERS
494	ENDOCRINE
494	CONSULTATIONS
494	SPECIALIST
495	YEARS
495	MONTH
495	MALES
495	AGE
495	AGES
495	FEMALES
495	1 MONTH
495	5 YEARS
496	ENDOCRINE DISORDERS
496	12.5
496	DIABETES
496	THYROID
496	PUBERTY
496	RICKETS
496	COMMON
496	DISORDERS
496	ENDOCRINE
496	THYROID DISORDERS
497	NUMBER
497	PAEDIATRIC
497	YEARLY
497	WAS A
497	PROGRESSIVE
497	NUMBER OF
497	SEEN
497	CASES
497	ENDOCRINE
497	INCREASE
498	12.5
498	FOLLOW UP
498	LOST
498	LOST TO FOLLOW UP
498	RECORDED
498	MORTALITY
498	VERY WELL
498	FOLLOW
498	REPORT
498	2.5
498	DOING
498	ALIVE
498	TIME
498	PATIENTS
499	ENDOCRINE DISORDERS
499	DIABETES
499	THYROID
499	PAEDIATRIC
499	PUBERTY
499	SEEN
499	RICKETS
499	LEADING
499	DISORDERS
499	ENDOCRINE
499	THYROID DISORDERS
500	ENDOCRINE DISORDERS
500	ATTRITION
500	PAEDIATRIC
500	CHALLENGE
500	NOTABLE
500	DISORDERS
500	ENDOCRINE
500	IS A
501	ATTRITION
501	CHALLENGES
501	PRACTICE
501	NEED
501	IDENTIFIED
501	TERMINATE
501	THESE
501	REASONS
502	KEYWORDS
503	ENDOCRINE DISORDERS
503	PAEDIATRIC
503	DIABETES
503	RICKETS
503	NIGERIA
503	AWARENESS
503	DISORDERS
503	ENDOCRINE
504	ECONOMIC
504	INEQUALITY
504	HOW
504	SOCIAL CAPITAL
504	LEVELS
504	AFFECT
504	SOCIAL
504	LOCAL
504	ECONOMIC INEQUALITY
504	CAPITAL
504	HOUSEHOLDS
504	CHANGING
505	BRIDGING
505	QUESTION
505	2002
505	IMPACT
505	HOUSEHOLD
505	LIVES
505	ECONOMIC
505	DATA
505	2014
505	LEVEL
505	VILLAGE
505	PROGRAMME
505	LEVELS
505	USING
505	SOCIAL
505	ECONOMIC INEQUALITY
505	NETWORK
505	YOUNG
505	SURVEYS
505	INEQUALITY
505	BONDING
505	SQUARES
505	STAGE
505	EXAMINING
505	CAPITAL
505	REGRESSIONS
505	ARTICLE
506	BRIDGING
506	MEASURED
506	SUGGEST
506	PARTICIPATION
506	ECONOMIC
506	HOMOGENEOUS
506	RISES
506	INCREASES
506	LOCAL
506	HOUSEHOLDS
506	RESOLVE
506	STUDY
506	SOCIAL
506	ECONOMIC INEQUALITY
506	ASSOCIATIONS
506	INEQUALITY
506	BONDING
506	MEMBERSHIP
506	SOCIAL CAPITAL
506	RESULTS
506	CAPITAL
506	VOLUNTARY
507	ECONOMIC
507	DEMOGRAPHIC
507	COMMUNITIES
507	CONFLICTS
507	CONTRIBUTE 
507	FRAGMENTATION
507	LIKELY
507	CONTRIBUTE
507	SOCIAL
507	DIVISION
507	EXISTING
507	RESEARCH
507	LINES
507	GROWING
508	PERIOPERATIVE
508	ATRIAL FIBRILLATION
508	RISK
508	CARDIAC SURGERY
508	CARDIAC
508	ASSOCIATED
508	INCREASED RISK
508	INCREASED
508	SURGERY
508	FIBRILLATION
508	RISK OF STROKE
508	RISK OF
508	ASSOCIATED WITH
508	STUDIES
508	ATRIAL
508	STROKE
509	EXACT
509	LONG
509	SHORT
509	LONG-TERM FOLLOW-UP
509	FOLLOW-UP
509	UNCLEAR
509	TERM
509	LONG-TERM
509	FOLLOW
509	SHORT-TERM
509	REMAINS
509	MAGNITUDE
509	ASSOCIATION
510	OCTOBER
510	TIME PERIOD
510	PERIOD
510	SEARCHED
510	CONTROLLED TRIALS
510	EMBASE
510	CENTRAL
510	DATABASE
510	CONTROLLED
510	TIME
510	PUBMED
510	TRIALS
510	2020
510	REGISTER
511	TERM
511	LONG-TERM
511	STROKE
511	PATIENTS
511	SHORT
511	CARDIAC SURGERY
511	OBSERVATIONAL STUDIES
511	DATA
511	CARDIAC
511	100
511	SURGERY
511	OBSERVATIONAL
511	INCLUDED
511	REPORTED
511	LONG
511	RISK
511	STROKE RISK
511	SHORT-TERM
511	STUDIES
512	POOLED
512	USING
512	DATA
512	EFFECTS
512	MODELS
512	RANDOM
513	CONFIDENCE
513	ADJUSTED
513	RATIOS
513	CIS
513	RISK
513	ABSOLUTE
513	RESULTS
513	RISK RATIOS
513	CALCULATED
513	CONFIDENCE INTERVALS
513	ABSOLUTE RISK
513	REPORTING
513	STUDIES
513	ARDS
513	RRS
513	SUMMARY
513	REPORTED
513	INTERVALS
514	540
514	INCLUDED
514	TOTAL
514	STUDIES
514	PATIENTS
515	TERM
515	41-2
515	ABSOLUTE RISK
515	STROKE
515	SHORT
515	ASSOCIATED WITH
515	ABSOLUTE
515	SUP
515	ARD
515	1.28
515	4.5
515	RISK
515	ASSOCIATED
515	RISK OF
515	2.0
515	RELATIVE
515	RELATIVE RISK
515	SHORT-TERM
515	2.5
515	STUDIES
515	INCREASED
516	12-1
516	YEARS
516	0.88
516	TERM
516	LONG-TERM
516	ABSOLUTE RISK
516	0.07
516	STROKE
516	0.18
516	PATIENT
516	ASSOCIATED WITH
516	1.06
516	ABSOLUTE
516	SUP
516	100
516	ARD
516	LONG
516	RISK
516	ASSOCIATED
516	RISK OF
516	RELATIVE
516	RELATIVE RISK
516	STUDIES
516	INCREASED
517	EMBOLIC
517	FINDINGS
517	EITHER
517	EMBOLIC STROKES
517	EMBOLIC 
517	STROKES
517	SIMILAR
517	REPORTING
517	HIGH
517	STUDIES
517	QUALITY
517	ISCHEMIC
517	SENSITIVITY ANALYSES
517	SENSITIVITY
518	LONG
518	SHORT
518	RISK
518	CARDIAC SURGERY
518	ASSOCIATED
518	CARDIAC
518	INCREASED RISK
518	RISK OF
518	SURGERY
518	TERM
518	LONG-TERM
518	ASSOCIATED WITH
518	SHORT-TERM
518	INCREASED
518	STROKE
519	LONG
519	ANTICOAGULATION
519	BENEFIT
519	TERM
519	ARD
519	LONG-TERM
519	SMALL
519	THERAPY
519	THESE
519	ORAL
519	ANTICOAGULATION THERAPY
519	STROKE
519	PATIENTS
519	UNCLEAR
520	CANADIAN
520	TRANSTHYRETIN
520	MANAGEMENT
520	AMYLOIDOSIS
520	TRANSTHYRETIN 
520	GUIDELINES 
520	AMYLOIDOSIS POLYNEUROPATHY
520	GUIDELINES
520	HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
520	TRANSTHYRETIN AMYLOIDOSIS
520	HEREDITARY
520	POLYNEUROPATHY
521	MEDIATED
521	DYSFUNCTION
521	TRANSTHYRETIN
521	AMYLOIDOSIS
521	PROGRESSIVE
521	ORGAN
521	TTR
521	TTR GENE
521	MUTATIONS
521	LEADING
521	CAUSED BY
521	PROGRESSIVE DISEASE
521	GENE
521	IS A
521	HEREDITARY
521	DISEASE
522	PERIPHERAL NERVE
522	NERVE
522	HEART
522	NERVE 
522	DEPOSITION
522	AMYLOID
522	TTR
522	SYSTEM
522	BODY
522	BODY ORGANS
522	ORGANS
522	FREQUENTLY
522	NERVE SYSTEM
522	AGGREGATION
522	PATHOGENIC
522	LEAD
522	PERIPHERAL
522	MULTIPLE
523	CARPAL TUNNEL
523	SENSORIMOTOR POLYNEUROPATHY
523	CARPAL TUNNEL SYNDROME
523	NEUROLOGIC MANIFESTATIONS
523	SYNDROME
523	AUTONOMIC
523	NEUROLOGIC
523	SMALL
523	TUNNEL
523	INCLUDE
523	SENSORIMOTOR
523	FIBER
523	NEUROPATHY
523	COMMON
523	CARPAL
523	AUTONOMIC NEUROPATHY
523	MANIFESTATIONS
523	POLYNEUROPATHY
524	DIFFERENTIAL DIAGNOSIS
524	DUE TO
524	SIGNIFICANT
524	DIFFERENTIAL
524	DIAGNOSIS
524	PROGRESSION
524	CONSIDERED
524	DIAGNOSTIC
524	PATIENTS
524	HAVE
525	NOVEL
525	RECENTLY
525	INOTERSEN
525	PATISIRAN
525	HEALTH
525	CANADA
525	APPROVED
525	THERAPIES
525	HEALTH CANADA
525	MODIFYING
525	TREATMENT
525	EFFECTIVE
525	APPROVED BY
525	DISEASE
526	EARLY DIAGNOSIS
526	EARLY
526	TIMELY
526	INTRODUCTION
526	REDUCE
526	LIFE
526	THESE
526	MODIFYING
526	IMPAIRMENTS
526	QUALITY
526	SURVIVAL
526	QUALITY OF LIFE
526	EXTEND
526	DIAGNOSIS
526	TREATMENTS
526	DISEASE
527	RECOMMENDATIONS
527	DIRECTED
527	MONITORING
527	GUIDELINE
527	OUTCOMES
527	TREATMENT
527	CANADA
527	AIM
527	AWARENESS
527	DIAGNOSIS
528	BACKGROUND
529	TESTING
529	PATCH
529	ASSIST
529	PATCH TESTING
529	PATIENTS
529	FORMULATION
529	WITH FOOD
529	AFR
529	ADVERSE
529	ELIMINATION DIETS
529	FOOD
529	PREVIOUS
529	FOOD EXTRACTS
529	ELIMINATION
529	SUSPECTED
529	HUMAN
529	DIETS
529	REACTIONS
529	STUDIES
529	HAVE
530	USE OF
530	USE
530	ABOUT
530	DOGS
530	KNOWN
530	LITTLE
530	THESE
530	TESTS
531	OBJECTIVES
532	PROTOCOLS
532	COMBINATION
532	TESTING
532	CHALLENGE
532	DOGS
532	PATCH
532	EFFECTIVENESS
532	PRICK
532	CURRENT
532	TESTS
532	FOOD
532	AFR
532	PATCH TESTING
532	EVALUATE
533	METHODS
533	MATERIALS
534	PRURITUS
534	DOGS
534	PATCH
534	PERFORMED
534	PRICK
534	PATCH TESTS
534	TESTS
534	CHRONIC
535	DOGS
535	FED
535	BASIS
535	RESULTS
536	CLINICAL SIGNS
536	IMPROVED
536	SIGNS
536	DOGS
536	CLINICAL
536	REACTION
536	POSITIVE
536	TESTS
536	FOOD
537	DOGS
537	NEGATIVE
537	FOOD
537	TESTING
538	EVALUATED
538	ATOPIC DERMATITIS
538	DERMATITIS
538	D60
538	D30
538	VISUAL
538	PVAS
538	PRURITUS
538	SEVERITY
538	CANINE
538	ANALOG
538	INDEX
538	4TH
538	ITERATION
538	ATOPIC
538	VISUAL ANALOG SCALE
538	SCALE
538	EXTENT
538	DAY
539	NPV
539	VALUES
539	KAPPA
539	PPV
539	PREDICTIVE
539	SPECIFICITY
539	POSITIVE
539	CALCULATED
539	SENSITIVITY
539	NEGATIVE
539	VALUE
540	RESULTS
541	WAS A
541	PVAS
541	D60
541	MEAN
541	DOGS
541	IMPROVEMENT
541	SIGNIFICANT
541	SCORES
541	D30
542	D30
542	D60
542	STATISTICAL
543	NPV
543	COMBINATION
543	VALUES
543	PPV
543	66.7
543	TESTS
543	80%
543	0.17
544	CONCLUSIONS
544	CLINICAL RELEVANCE
544	RELEVANCE
544	CLINICAL
545	NPV
545	COMBINATION
545	TESTING
545	VALUES
545	PATCH
545	PRICK
545	PATCH TESTING
545	HIGH
546	TEST
546	SELECTION
546	DOGS
546	TEST RESULTS
546	RESULTS
546	USEFUL
546	AFR
546	DIAGNOSIS
547	PROBLEMS
547	IMAGING
547	NEUROIMAGING
547	MODALITIES
547	INFORMATION
547	ONE OF
547	DIFFERENT
547	IMAGING MODALITIES
548	RESULT
548	LOSS OF
548	MUTUAL
548	INSTANCE
548	DIMENSIONALITY
548	DATA
548	USING
548	REDUCTION
548	LOSS
548	TECHNIQUES
548	FREQUENTLY
548	INFORMATION
548	MODALITY
548	ANALYZED
548	DIMENSIONALITY REDUCTION
549	NOVEL
549	METHOD
549	LINEAR
549	EMPIRICAL
549	PARTIALLY
549	OUTCOME
549	STRUCTURE
549	GENERALIZED
549	SCALAR
549	ESTIMATE
549	BRAIN STRUCTURE
549	LINEAR REGRESSION
549	FEATURES
549	REGRESSION
549	FRAMEWORK
549	ASSOCIATIONS
549	BRAIN
549	EIGENVECTORS
549	THE BRAIN
550	APPROACH
550	BRAIN CONNECTIVITY
550	REGRESSION COEFFICIENT
550	USE
550	STRUCTURAL
550	CONNECTIVITY
550	COEFFICIENT
550	IMPROVES
550	REGRESSION
550	INFORMATION
550	BRAIN
550	EXTERNAL
550	PROVIDING
550	ESTIMATION
551	LINEAR REGRESSION
551	CONNECTIVITY
551	STRUCTURAL
551	PENALTY
551	TERM
551	GENERALIZED
551	REGRESSION
551	MATRIX
551	LINEAR
551	LAPLACIAN
551	DERIVED
552	WORK
552	BRAIN CONNECTIVITY
552	COMPUTATIONAL
552	METHOD
552	ABOUT
552	STRUCTURAL
552	CONNECTIVITY
552	THEORETICAL
552	OUR
552	INCOMPLETE
552	ADDRESS
552	INFORMATION
552	BRAIN
553	PROVIDE
553	TESTING
553	INFERENCE
553	PROCEDURE
553	ESTIMATED
553	PERFORMING
553	COEFFICIENTS
553	SIGNIFICANCE
553	ADDITION
554	HIV
554	EVALUATED
554	CLINICAL
554	EXTENSIVE
554	USING
554	DATA
554	HIV+
554	STUDIES
554	CLASSIFY
554	INDIVIDUALS
554	SIMULATION
554	CLINICAL DATA
556	HEALTHY
556	BEHAVIOURS
556	LIMITED
556	TIME
556	AMOUNTS
556	FOUNDATIONS
556	DEVELOPMENT
556	SCREEN
556	PHYSICAL
556	MAINTENANCE
556	ADOPTION
556	APPROPRIATE
556	SCREEN TIME
556	PHYSICAL ACTIVITY
556	AGE-APPROPRIATE
556	INCLUDING
556	HEALTHY EATING
556	ACTIVITY
556	YOUTH
556	AGE
556	EATING
556	SEDENTARY
557	REVIEWING
557	TIME
557	SEDENTARY
557	EXTANT
557	SCREEN
557	EVIDENCE
557	PHYSICAL
557	ASSOCIATED WITH
557	INCREASED FOOD INTAKE
557	SNACKING
557	MARKED
557	FOOD INTAKE
557	SCREEN TIME
557	FOOD
557	PHYSICAL ACTIVITY
557	REDUCTIONS
557	ACTIVITY
557	INTAKE
557	COVID-19
557	ASSOCIATED
557	UNHEALTHY
557	PANDEMIC
557	OBSERVE
557	INCREASED
557	COVID-19 PANDEMIC
558	DELETERIOUS
558	WIDESPREAD
558	MOVEMENT
558	BEHAVIOURS
558	FOOD INSECURITY
558	EFFECTS
558	FOOD
558	INSECURITY
558	APPEAR
558	GROUPS
558	PRONOUNCED
558	VULNERABLE
559	PUBLIC HEALTH
559	CONTRIBUTE 
559	IMPACTS
559	EVIDENCE
559	CONTRIBUTE
559	HEALTH
559	BASED
559	THESE
559	ADVOCATE
559	PUBLIC
560	INEQUALITIES
560	ADDITIONAL
560	AUGMENTED
560	ONGOING
560	INDICATORS
560	SOCIAL
560	SOCIAL INEQUALITIES
560	END
560	SURVEILLANCE
561	PRESSURE
561	HYPERTENSION
561	PULMONARY
561	POSTCAPILLARY PULMONARY HYPERTENSION
561	PULMONARY ARTERY WEDGE PRESSURE
561	WEDGE
561	PULMONARY ARTERY WEDGE
561	MEAN
561	PULMONARY ARTERY
561	ARTERY
561	WEDGE PRESSURE
561	PULMONARY HYPERTENSION
561	DIFFERENTIATION
562	VENTRICULAR
562	END-DIASTOLIC
562	PRESSURE
562	LEFT VENTRICULAR END-DIASTOLIC PRESSURE
562	ALTERNATIVE
562	DIASTOLIC
562	EQUIVALENT
562	LVEDP
562	PROPOSED
562	LEFT
562	END
562	DIASTOLIC PRESSURE
563	LVEDP
564	CLASSIFICATION
564	PREDICTION
564	REPLACEMENT
564	VALVE REPLACEMENT
564	AORTIC
564	COMPARED
564	USING
564	IMPACT
564	MORTALITY
564	STENOSIS
564	SEVERE
564	VALVE
564	CHOICE
564	LVEDP
564	PATIENTS
564	AORTIC STENOSIS
565	335
565	SEVERE
565	MEASURED
565	LVEDP
565	PATIENTS
566	PRESSURE
566	DIFFERENTIATE
566	PULMONARY
566	EITHER
566	USED
566	MEAN
566	ARTERY PRESSURE
566	PULMONARY ARTERY
566	ARTERY
566	MM HG
566	PULMONARY ARTERY PRESSURE
566	LVEDP
567	AORTIC VALVE REPLACEMENT
567	REPLACEMENT
567	VALVE REPLACEMENT
567	AORTIC
567	FOLLOW-UP
567	MEDIAN
567	ASSESSED
567	MORTALITY
567	FOLLOW
567	DAYS
567	VALVE
567	AORTIC VALVE
568	0.001
568	MM HG
568	OVERALL
568	001
568	LVEDP
568	LOWER
569	CLASSIFICATION
569	REVEALED
569	PAWP
569	BASED
569	PRE
569	ISOLATED
569	140
569	PATIENTS
569	COMBINED
570	CLASSIFIED
570	LVEDP
570	PATIENTS
570	USED
571	CONFIDENCE
571	CONFIDENCE INTERVAL
571	RATIO
571	HAZARD
571	HAZARD RATIO
571	MORTALITY
571	CLASSIFIED
571	INTERVAL
571	1.17
571	THESE
571	95% CONFIDENCE INTERVAL
571	0.02
571	HIGHER MORTALITY
571	PATIENTS
571	HIGHER
572	CONFIDENCE
572	CONFIDENCE INTERVAL
572	RATIO
572	HAZARD
572	HAZARD RATIO
572	ASSOCIATED
572	0.001
572	MORTALITY
572	1 MM
572	MM HG
572	INTERVAL
572	ASSOCIATED WITH
572	95% CONFIDENCE INTERVAL
572	001
572	INCREASED MORTALITY
572	INCREASED
572	LVEDP
572	HIGHER
573	CLASSIFICATION
573	USE OF
573	NEARLY
573	USE
573	PATIENT
573	RESULTS
573	RATHER
573	SEVERE
573	SECOND
573	EVERY SECOND
573	DIVERGENT
573	LVEDP
574	AORTIC VALVE
574	AORTIC VALVE REPLACEMENT
574	REPLACEMENT
574	VALVE REPLACEMENT
574	AORTIC
574	MORTALITY
574	VALVE
574	THESE
574	HIGHER MORTALITY
574	HAVE
574	PATIENTS
574	HIGHER
575	LVEDP
575	BUT
575	MORTALITY
576	HEALTHY
576	DYNAMIC
576	DETERMINE
576	INFLUENCE
576	FATIGUE
576	INDUCED
576	BALANCE
576	ATHLETES
577	REVIEW
577	SYSTEMATIC REVIEW
578	LIBRARY
578	SPORTS
578	2019
578	MEDLINE
578	ONSET
578	PUBMED
578	DISCUS
579	STUDY
579	HEALTHY
579	DYNAMIC
579	ELIGIBLE
579	YBT
579	ATHLETIC
579	EFFECTS
579	EXAMINING
579	INCLUDED
579	INDUCED
579	STUDIES
579	FATIGUE
579	BALANCE
579	POPULATIONS
579	MEASURED
580	BEST
580	BIAS
580	LOW RISK
580	RISK
580	SYNTHESIS
580	RISK OF BIAS
580	RISK OF
580	EVIDENCE
580	EVIDENCE SYNTHESIS
580	LOW
580	STUDIES
580	CONSIDERED
581	COMPETITIVE
581	INVESTIGATED
581	BIAS
581	LOW RISK
581	RISK
581	FOCUSED
581	FIFTEEN
581	RISK OF BIAS
581	RISK OF
581	SEVEN
581	LOW
581	INCLUDED
581	STUDIES
581	RECREATIONAL
581	ATHLETES
582	POPULATION
582	DYNAMIC
582	FATIGUING
582	INTERVENTION
582	SIGNIFICANT
582	FOUND
582	DECREASE
582	BALANCE
582	STUDIES
582	FOLLOWING
582	SIGNIFICANT DECREASE
582	RECREATIONAL
583	CHANGES
583	REMAINING
583	INSIGNIFICANT
584	COMPETITIVE
584	POPULATION
584	DYNAMIC
584	SIGNIFICANT
584	EFFECTS
584	FATIGUE
584	INDUCED
584	STUDIES
584	BALANCE
585	DYNAMIC
585	CONFLICTING
585	RESULTS
585	EFFECTS
585	FATIGUE
585	INDUCED
585	BALANCE
586	COMPETITIVE
586	ALTER
586	DYNAMIC
586	FOCUSED
586	FOUND
586	MAJORITY
586	FATIGUE
586	STUDIES
586	BALANCE
586	ATHLETES
586	DID
587	DYNAMIC
587	FOCUSED
587	AFFECT
587	CONTRA
587	MAJORITY
587	FATIGUE
587	STUDIES
587	OPPOSITE
587	BALANCE
587	RECREATIONAL
587	ATHLETES
587	DID
